




What has changed in venous thromboembolism prophylaxis for hospitalized patients over recent decades: review article

O que mudou nas últimas décadas na profilaxia do tromboembolismo venoso em pacientes internados: artigo de revisão

Selma Regina de Oliveira Raymundo^{1,2} , Suzana Margareth Ajeje Lobo¹, Kassim Mohamede Kassim Hussain¹, Kassim Guzzon Hussein³, Isabela Tobal Secches³

Abstract

Venous thromboembolism (VTE) is a common disease with high rates of morbidity and mortality and is considered the number one cause of avoidable mortality among hospitalized patients. Although VTE incidence is extremely high in all countries and there is ample evidence that thromboprophylaxis inexpensively reduces the rate of thromboembolic complications in both clinical and surgical patients, a great deal of doubt remains with respect to patient safety with this type of intervention and in relation to the ideal thromboprophylaxis methods. Countless studies and evidence-based recommendations confirm the efficacy of prophylaxis for prevention of VTE and/or patient deaths, but it remains underutilized to this day. This article presents a wide-ranging review of existing prophylaxis methods up to the present, from guidelines and national and international studies of thromboprophylaxis.

Keywords: venous thromboembolism; prevention & control; anticoagulants.

Resumo

O tromboembolismo venoso (TEV) é uma doença frequente e de alta morbimortalidade, sendo considerada a maior causa evitável de mortalidade em pacientes hospitalizados. Apesar da incidência altíssima de TEV em todos os países e das evidências de que a tromboprofilaxia reduz as complicações tromboembólicas em pacientes clínicos e cirúrgicos, e a custo baixo, persistem grandes dúvidas quanto à segurança desse tipo de intervenção nos pacientes e quanto à tromboprofilaxia ideal. Inúmeros estudos e recomendações baseadas em evidências comprovam a eficácia da profilaxia na prevenção do TEV e/ou da morte dos pacientes, mas ainda hoje ela é subutilizada. Neste artigo, apresentamos uma ampla revisão dos métodos de profilaxia existentes até os dias atuais, publicados em diretrizes e estudos nacionais e internacionais sobre tromboprofilaxia.

Palavras-chave: tromboembolismo venoso; prevenção & controle; anticoagulantes.

How to cite: Raymundo SRO, Lobo SMA, Hussain KMK, Hussein KG, Secches IT. What has changed in venous thromboembolism prophylaxis for hospitalized patients over recent decades: review article. J Vasc Bras. 2019;18:e20180021. <https://doi.org/10.1590/1677-5449.002118>

¹Faculdade Regional de Medicina de São José do Rio Preto – FAMERP, Hospital de Base, São José do Rio Preto, SP, Brasil.

²Hospital Austa, São José do Rio Preto, SP, Brasil.

³Faculdade de Medicina em São José do Rio Preto – FACERES, São José do Rio Preto, SP, Brasil.

Financial support: None.

Conflicts of interest: No conflicts of interest declared concerning the publication of this article.

Submitted: May 17, 2018. Accepted: November 13, 2018.

The study was carried out at Hospital Austa, São José do Rio Preto, SP, Brazil.

■ INTRODUCTION

Deep venous thrombosis (DVT) and pulmonary embolism (PE) are severe public health problems on both the national and international scales, due to the elevated costs associated with acute episodes of venous thromboembolism (VTE) and their long term complications.^{1,2} Venous thromboembolism is a serious complication in hospitalized patients and the most common cause of avoidable deaths among these patients, in addition to being the third-ranked cardiovascular cause of death, after coronary disease and strokes.³

It is now clear that clinical patients are as much at risk of VTE as surgical patients. Patients who undergo orthopedic surgery or general surgery and those with acute myocardial infarction are at high risk of VTE, and the proportions are almost equal among surgical and clinical patients (22 and 24% respectively).⁴ The rate of symptomatic VTE among abdominal surgery patients is in the range of 0.4 to 3.1%.⁵

Immobilization caused by lower limb paralysis or confinement for more than 3 days, severe trauma, and spinal cord trauma can increase the risk of thrombosis by as much as ten times, and the effect is cumulative over time.^{6,7} Hospitalized patients with acute clinical diseases are also at significant risk: approximately 10 to 30% of clinical patients develop VTE.² Congestive heart failure (CHF) and respiratory failure also increase the risk of thrombosis by up to ten times.⁷

The frequency of thromboembolic complications among hospitalized patients, the adverse consequences of these events, and their economic impact justify prioritizing thromboprophylaxis for the safety of these patients, since it is a significant factor in reducing short and long term morbidity and mortality. However, despite the extremely high incidence of VTE recorded and published in many different studies and the evidence that thromboprophylaxis reduces thromboembolic complications among clinical and surgical patients at low cost, there is still a great deal of doubt with relation to the safety of this type of intervention and to the ideal prophylaxis methods. This situation remains despite more than five decades having passed since the first published study demonstrating that the rate of fatal and symptomatic VTE can be reduced by prophylaxis and almost 30 years since the first evidence-based guideline recommending prophylaxis for the majority of hospitalized patients.

This article presents a wide-ranging review of the literature on thromboprophylaxis, based on a systematic analysis of bibliographic references from the PubMed, SciELO, MEDLINE, and LILACS databases for the

period 1990-2017 and of selected articles from the CAPES periodicals portal.

The objective of this article is to raise awareness of the need for thromboprophylaxis and of strategies for increasing compliance, since, in spite of all efforts, rates are still unsatisfactory all over the world.

■ PROPHYLAXIS METHODS

There are now many thromboprophylaxis methods available. Non-pharmacological methods, including elastic graduated compression stockings (EGCS), intermittent pneumatic compression (IPC), and venous pumps for feet, have proven effective for reduction of DVT in several patient groups.^{2,8} While these mechanical methods do not increase the risk of bleeding, there are few studies of such devices and they appear to be less effective than pharmacological prophylaxis in some groups.² According to current evidence, mechanical prophylaxis methods are more often used with patients at high risk of bleeding or in combination with pharmacological prophylaxis, to attempt to increase its efficacy.²

Many effective prophylaxis strategies, such as combinations of IPC, EGCS, or pharmacological prophylaxis (acetylsalicylic acid [AAS] or anticoagulants) in high-risk patients, are not included in the guidelines because there are few randomized clinical trials, when compared to any of the options that are recommended, and also because these combinations may not be effective, but are more complex and expensive than simple options.⁸⁻¹¹

The International Multicenter Trial on PE prevention described by Kakkar is the point of reference for the start of pharmacological prophylaxis and demonstrated that 5,000 international units (IU) of unfractionated heparin (UFH) subcutaneously three times a day reduced the rate of DVT by 25%, while in the group control this reduction was 8%. Fatal PE was eight times less frequent in patients undergoing major surgery.¹² A meta-analysis conducted some years later, of 46 randomized clinical trials including 15,000 surgical patients, demonstrated a reduction in asymptomatic DVT and fatal PE exceeding 60% and significant reductions in their mortality, even when low doses of UFH were used.¹³

Low molecular weight heparin (LMWH) is a more effective prophylaxis option for a large number of patients and tends to be used as a substitute for UFH.^{2,14} Low molecular weight heparin has rapid onset of action, requires a single daily dose and, in many countries, is of low cost. Currently, two types of LMWH are available commercially in Brazil: enoxaparin and dalteparin.

Oral vitamin K antagonists (VKA), such as warfarin, have been used for prophylaxis in major orthopedic surgery for several decades and, when used correctly, are effective for reducing VTE rates, but they have certain disadvantages: slow onset of action, large variations in dosage from patient to patient, and higher rates of bleeding when prophylaxis is of long duration.^{2,8,15}

A synthetic indirect factor Xa inhibitor (fondaparinux) demonstrated greater efficacy than LMWH in more than 7,000 orthopedic surgery patients in a meta-analysis of four randomized studies.¹⁶ It was also effective in studies of prophylaxis for general surgery and clinical patients.^{17,18}

For a considerable length of time, the anticoagulants available did not meet criteria for a theoretically ideal anticoagulant, which stimulated researchers to investigate new molecules, with more predictable pharmacokinetics and pharmacodynamics and which would more closely approach the ideal profile of efficacy, safety, and posological comfort. The direct oral anticoagulants¹⁹ rivaroxaban, apixaban, and edoxaban (direct factor X inhibitors) and dabigatran etexilate (a direct thrombin inhibitor) have been approved in some countries for prevention of VTE after total hip arthroplasty (THA) and total knee arthroplasty (TKA). Rivaroxaban was evaluated in four large phase III trials. These double-blind studies, entitled Regulation of Coagulation in Major Orthopedic Surgery Reducing Risk of Deep Venous Thrombosis and Pulmonary Embolism (RECORD) enrolled more than 12,500 elective THA and TKA surgery patients and demonstrated the superiority of rivaroxaban, at a dosage of 10 mg per day, with a reduction of more than 50% in the risk of symptomatic VTE and death, when compared with 40 mg/day of enoxaparin.²⁰ However, the risk of bleeding with rivaroxaban was 0.7% compared to 0.3% with enoxaparin.

The RECORD1 study compared the efficacy of rivaroxaban with enoxaparin during the postoperative period for 5 weeks in THA patients and found a 70% reduction in the relative risk of the primary efficacy outcome when rivaroxaban was used.²¹ RECORD2 was a trial designed to study superiority by comparing extended VTE prophylaxis with 10 mg rivaroxaban over 35±4 days with short term prophylaxis with 40 mg of subcutaneous enoxaparin for 10-14 days followed by an oral placebo up to 35±4 days after THA.²² Extended thromboprophylaxis with rivaroxaban was significantly more effective, with a 79% reduction in the relative risk of the primary efficacy outcome and superior prevention of symptomatic events.

RECORD3 was the first study to show a significant reduction in symptomatic VTE among

TKA patients, showing the superior efficacy of a 10 mg daily oral dose of rivaroxaban over enoxaparin for 10 to 14 days.²³ In turn, the RECORD4 trial compared the efficacy of 10 mg rivaroxaban per day with 30 mg of enoxaparin, subcutaneously twice a day for a period of 10 to 14 days in patients subjected to TKA, demonstrating that rivaroxaban was not inferior and was associated with a 31% reduction in relative risk of the primary efficacy outcome, in addition to numerical reductions in the secondary efficacy outcomes and symptomatic VTE rates, although these reductions were not significant.²⁴

Apixaban is easily absorbed orally and clearance is renal (25-30%) and hepatic (65%).²⁵ In the ADVANCE1 study, apixaban, at a dosage of 2.5 mg twice a day, was not inferior when compared to enoxaparin (30 mg every 12 hours) in TKA patients, but the outcomes, mortality, and VTE study were similar, while apixaban was associated with a lower rate of bleeding.^{26,27}

The ADVANCE2 study, with TKA patients, confirmed that apixaban, at a dosage of 2.5 mg twice a day for 10 to 14 days, was more effective than enoxaparin (40 mg/day), with similar safety.^{25,28} The ADVANCE3 study compared apixaban and enoxaparin over 32 to 38 days in THA patients. Apixaban exhibited a statistically superior reduction in the primary outcome (presence of VTE), in death from all causes, and in the composite outcome proximal DVT, non-fatal PE, and VTE-related death.

A phase III trial compared edoxaban at a dosage of 30 mg once a day with 20 mg enoxaparin every 12 hours for TKA prophylaxis. The efficacy results for edoxaban were superior to those for enoxaparin at this dosage, and safety (bleeding) was similar.²⁹

Dabigatran was used for DVT prophylaxis in TKA and THA surgery in three phase III trials (RE-MODEL, RE-MOBILIZE, and RE-NOVATE), which demonstrated it was not inferior to LMWH. Dabigatran was tested at doses of 150 or 220 mg/day during the postoperative period after THA vs. 40 mg/day enoxaparin (RE-NOVATE) and vs. 30 mg enoxaparin twice a day (RE-MOBILIZE). The primary outcome used for analysis was the rate of DVT, VTE and/or death from all causes.^{25,30-32}

It is currently recommended that pharmaceutical prophylaxis should be extended up to 35 days in certain situations, such as orthopedic surgery (TKA, THA, and surgery for hip fractures), because the majority of symptomatic thromboembolic events are diagnosed after discharge and an increased risk of VTE remains for more than 3 months after THA and for more than 1 month after TKA.³³

A meta-analysis of nine randomized studies with a total of 4,000 major orthopedic surgery patients found a 51% reduction in risk of DVT and 61% for symptomatic VTE with extended prophylaxis, without increased bleeding.³⁴

Extended use of fondaparinux for 7 days in patients with hip fractures eliminated asymptomatic DVT and symptomatic VTE.³⁵ Although prophylaxis lasting from 4 to 6 weeks is superior to prophylaxis only given while in hospital, the optimum duration between 2 and 6 weeks is unknown. Extended prophylaxis is also suggested for patients undergoing major cancer surgery. Two studies showed that among these patients extended prophylaxis lasting 4 weeks was associated with reductions in the DVT rate, when compared with just 1 week.³⁶

■ PROPHYLAXIS RECOMMENDATIONS FROM THE AMERICAN COLLEGE OF CHEST PHYSICIANS (ACCP) EVIDENCE-BASED CLINICAL PRACTICE GUIDELINES

In 1959, publication of a controlled trial of thromboprophylaxis demonstrated that use of an oral anticoagulant in patients undergoing surgical treatment for hip fractures reduced symptomatic VTE and deaths, without increasing clinically significant bleeding.³⁷ Since that study, hundred of others have been conducted and new prophylaxis options have been evaluated, adopted, and, in some cases, substituted by more effective and safer methods. Since 1986, more than 25 evidence-based guidelines have been published recommending routine thromboprophylaxis for the majority of hospitalized patients.^{2,38} Every 4 years, the American College of Chest Physicians (ACCP) publishes guidelines for treatment and prevention of VTE³⁹ which are a reference worldwide. A quality-based approach has been taken to classification of evidence grades and recommendations since the sixth edition of the ACCP guidelines.⁴⁰ The eighth edition (AT8), from 2008, discusses the risks and evidence for thromboprophylaxis for 23 different groups of patients separately, with emphasis on randomized clinical trials² (RCT) and classifies recommendations and the methodological quality of the evidence supporting them as follows:⁴¹

Recommendation grades:

- Grade 1: the benefits outweigh harms, burden, and costs;
- Grade 2: individual patient characteristics may lead to different choices.

Evidence level:

- A (high quality): results are from well-planned and conducted RCTs, with parallel groups and adequate controls, appropriate data analysis, and consistent findings;
- B (moderate): from RCTs with small confidence intervals, or cohort, case-control, or observational studies;
- C (low): results from cohort and case-control studies of low quality with a high likelihood of bias.

Recommendation options in favor of or against thromboprophylaxis are described for each group of patients and it is recommended that every hospital should develop its own formal strategy for VTE prevention (Grade 1A) and that thromboprophylaxis should be provided for many hospitalized patients. Use of AAS in isolation was not recommended for any patient group (Grade 1A) and mechanical methods are primarily recommended for patients with a high risk of bleeding (Grade 1A) or as an adjuvant to pharmacological prophylaxis (Grade 2A).

In the ninth edition (AT9), from 2012, many recommendations with lower impact substituted the higher impact recommendations in the AT8, because of a more critical evaluation of the inferences underlying evidence and exclusion of specialists with conflicts of interests from the final recommendation process.⁴² One limitation of the AT8 was an inconsistent approach to evaluation of risk of bleeding, which was corrected in AT9, where this risk was applied in all chapters.⁴³ Many new recommendations were added in this edition, but a large number of them had low evidence levels (2C).

■ STUDIES OF PROPHYLAXIS IN CLINICAL PATIENTS

The Prophylaxis in Medical Patients with Enoxaparin (MEDENOX) trial was the first multicenter randomized study to evaluate efficacy and safety of pharmacological prophylaxis in patients with acute clinical diseases and demonstrate the risk of VTE among these patients.

Patients over the age of 40 years admitted with CHF or acute respiratory failure without a need for ventilatory support, or patients with other clinical conditions and at least one risk factor for VTE (age over 75 years, cancer, prior VTE, hormone therapy, obesity, varicose veins, or chronic heart or respiratory failure) were randomized to receive placebo or enoxaparin, daily, at doses of 20 and 40 mg, over periods ranging from 6 to 14 days. The incidence of VTE in the 1,102 patients was significantly lower

among those given 40 mg of enoxaparin (5.5%) than in groups given placebo (14.9%) or 20 mg of enoxaparin (15%). The observed benefit of 40 mg of enoxaparin was maintained for 3 months. The incidence of adverse effects did not differ significantly between the placebo group and the enoxaparin group.⁴⁴ This study therefore documented the incidence of VTE in clinical patients and also established the efficacy of prophylaxis and the appropriate dose. An increased risk of VTE was also observed after hospital discharge, since the symptomatic DVT rate at 110 days was double the rate observed at 14 days. The objective of the THE-PRINCE⁴⁵ randomized study was to determine the efficacy and safety of 40 mg of subcutaneous enoxaparin, once a day, or 5000 IU of UFH three times a day over 10±2 days, in patients with CHF or severe respiratory disease. The incidence of VTE was 8.4% in the enoxaparin group and 10.4% in the UFH group. Enoxaparin was associated with fewer deaths, bleeding events, and adverse effects. The study concluded that enoxaparin was, at least, as effective as UFH for preventing VTE in these clinical patients and offered a better safety profile.

In the multicenter, randomized PREVENT⁴⁶ study, 1,518 clinical patients were given 5,000 IU of subcutaneous dalteparin once a day and 1,473 were given placebo for 14 days. Dalteparin reduced the rate of VTE to 2.8% without increasing the major hemorrhage rate, compared to the placebo group, with an incidence of 4.9%. This study also showed the need for pharmacological prophylaxis in these patients and established the efficacy and safety of dalteparin.

The ARTEMIS study¹⁸ evaluated the efficacy and safety of 2.5 mg fondaparinux used for a period ranging from 6 to 10 days for prevention of VTE in older clinical patients, comparing it with placebo. The incidence of VTE was 10% among patients who received placebo and 5.6% among those given fondaparinux.

The PREVAIL study,⁴⁷ which assessed use of LMWH in patients with ischemic strokes, observed a DVT prevalence of 20 to 50% and observed that PE was the third most common cause of death. The study assessed 1,762 patients who were unable to walk and had suffered acute ischemic stroke within 48 hours of admission, randomized to receive 5000 IU of UFH twice a day or 40 mg of enoxaparin in a single daily dose, for 10 days. Enoxaparin was more effective than UFH for reduction of VTE in these patients (18% vs. 10%), with the same incidence of major intracranial and extracranial hemorrhages (1%).

The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) was an

observational study that evaluated practices for VTE prevention in 15,156 hospitalized clinical patients in twelve countries over 4 years, finding that 50% of the patients received pharmaceutical or mechanical thromboprophylaxis. In the United States, 52% of the patients should have been given thromboprophylaxis, but only 60% of patients with risk factors for VTE actually were given it. In the United States, UFH was the most frequently used drug (20%), whereas LMWH was used most often in the other countries studied (40%).⁴⁸

The EXCLAIM⁴⁹ randomized study was conducted with the objective of establishing the appropriate duration of thromboprophylaxis in patients over the age of 40 years hospitalized for acute clinical diseases and immobilized for up to 3 days. In this study, 40 mg enoxaparin was prescribed once a day for 10±4 days, followed by enoxaparin 40 mg once a day or placebo for a further 28±4 days. Compared to placebo, extended treatment with enoxaparin reduced the relative risk of all VTE events by 44% (from 4.9% to 2.8%), of asymptomatic VTE by 34%, and of symptomatic VTE by 73%. In a subset of patients with level 1 immobility (completely confined to bed), VTE was observed in 2.5% of patients given enoxaparin, compared with 4% in the placebo group. The risk of major bleeding was 0.8% in the group given extended enoxaparin and 0.3% in the placebo group. These results demonstrated a 1.5% reduction in the incidence of proximal VTE or PE, at the expense of a 0.5% increase in the incidence of major bleeding. The study concluded that the extended regimen with enoxaparin is safe and effective in clinical patients who remain immobilized.

A large, observational, multicenter study assessed the prevalence of VTE in hospitalized clinical patients over the age of 40 years, or over the age of 18 years admitted for surgical treatment or because of traumas, and also studied the proportion of at-risk patients given the appropriate prophylaxis (Epidemiologic International Day for the Evaluation of Patients at Risk of Venous Thrombosis in the Acute Hospital Care Setting, ENDORSE). The study reviewed 37,356 (55%) medical records for clinical patients and 30,827 (45%) for surgical patients against the seventh edition of the ACCP guidelines. The proportion of patients considered at risk of VTE ranged from 36 to 73%.⁵⁰ The proportion of at-risk patients who were given appropriate prophylaxis ranged from 2 to 84% in different countries. Among the surgical patients, 64.4% were at risk of VTE, 58.5% were given prophylaxis and, despite 41.5% of the clinical patients being considered at risk, just 39.5% of them were given appropriate prophylaxis. This study demonstrated

that, overall, more than 50% of the hospitalized clinical patients needed prophylaxis, but just half of them received it, and that prophylaxis was given to a greater proportion of surgical patients. Furthermore, the study also showed the existence of a large gap in terms of administration of adequate prophylaxis to the population at risk, particularly among clinical patients.

After publication of the MEDENOX study, prophylaxis with enoxaparin was once more evaluated in a double-blind, placebo-controlled, randomized study entitled Low-Molecular-Weight Heparin and Mortality in Acutely Ill Medical Patients (LIFENOX), with the objective of evaluating 30-day all-causes mortality after use of 40 mg of subcutaneous enoxaparin for 10±4 days, compared to placebo.⁵¹ The patients enrolled were over the age of 40 years and had been hospitalized due to acute decompensated CHF, active cancer, or severe systemic infection and one additional condition or risk factor (chronic lung disease, obesity, prior history of VTE or age ≥ 60 years). A total of 8,307 patients who spent at least 6 days in hospital were assessed.

At 30 days, no significant difference was observed between the enoxaparin and placebo groups in terms of the primary outcome, which was all-causes mortality (4.9% vs. 4.8%, respectively). The study confirmed the need for continued use of pharmacological prophylaxis to prevent VTE and its nonfatal complications in clinically ill hospitalized patients. However, this study suffered from several limitations: 1) the rate of events in the placebo group was lower (4.8%) than expected (7%), and the rate of fatal PE in the placebo group was less than 0.1% at 30 days; 2) patients were younger, with less overweight and had had fewer prior thromboembolic events; and 3) mobility, a major determinant of risk of VTE, was also not assessed, which could have led to selection of patients with lower rates of events.

The MAGELLAN⁵² study compared use of 10 mg rivaroxaban per day for extended prophylaxis over 35±4 days with a standard regimen of 10±4 days of enoxaparin (40 mg/day, subcutaneous) in acutely ill clinical patients. A total of 8,101 patients were randomized 1:1 for extended rivaroxaban or enoxaparin. The results of the study confirmed that events related to VTE continue to occur after hospital discharge. There was an increase in the rate of events in the control group from 2.7% at 10 days to 5.7% at 35 days, and a 4.4% rate in the rivaroxaban group, confirming its efficacy for reducing the rate of events; however, the data suggested that the increased risk of major bleeding in this group (1.1% vs. 0.4%) could lead to its use not being recommendable. Clinically relevant bleeding at 35 days was also observed in 4.1% of the

patients in the rivaroxaban group and in 1.7% of the control group.

The multinational Assessment for VTE management in hospital-Middle East (AVAIL ME)⁵³ study enrolled clinical and surgical patients with the primary objective of identifying the prevalence of patients at risk of VTE and determining the proportion of hospitalized patients who were given prophylaxis in accordance with the 2004 ACCP guidelines. The authors observed that VTE risk factors and eligibility for prophylaxis were common (exceeding 80%), but rates of prophylaxis and compliance with guidelines were low (37%), and showed that fewer clinical patients were given pharmaceutical prophylaxis than surgical patients.

The AVAIL ME Extension Project was published in 2011. Among patients eligible for VTE prophylaxis, 77% were given some type of pharmaceutical prophylaxis, and there was 38% compliance with the AT8 guidelines.⁵⁴ In this study, although prophylaxis was apparently being administered with greater frequency than seen in previous reports, a significant percentage of patients were given prophylaxis in the absence of any clear indication of need (78%) or even in the presence of documented contraindications (66%), and clinical patients were given prophylaxis less than surgical patients.

An observational cohort study in the United States enrolled 294,896 critically ill patients admitted to intensive care units (ICU) and treated with pharmacological thromboprophylaxis, with mechanical methods, with both, or not given prophylaxis. The main finding of this study is that adult ICU patients on prophylaxis with anticoagulants had a lower risk of mortality than those using mechanical methods or not given any type of prophylaxis. These findings confirm the recommendation of pharmaceutical prophylaxis rather than mechanical prophylaxis for critical patients who do not have any contraindications to anticoagulation.⁵⁵

■ BRAZILIAN STUDIES OF THROMBOPROPHYLAXIS

In Brazil, the guidelines for VTE risk factors and risk stratification and thromboembolic recommendations are certified by the Brazilian Medical Association (Associação Médica Brasileira).^{56,57}

A study conducted from 1995 to 1999 at the Hospital Naval Marcílio Dias (Rio de Janeiro) analyzed 18,690 patients using Caprini risk stratification, classifying 5% of them as at high risk, 43% as intermediate, and 52% as low risk. The authors observed that the recommended prophylaxis was adopted in 47% of high risk patients, that 33% of moderate risk patients were not given prophylaxis, and that 4.6% of low risk patients were given pharmaceutical prophylaxis,

despite not having indications.⁵⁸ The 4 years of this pilot study confirmed the viability and value of the register and revealed a considerable increase in use of LMWH, associated with a six fold reduction in the incidence of symptomatic VTE.

A new multicenter study was conducted investigating the incidence and distribution of risk factors for VTE in clinical, surgical, and obstetric-gynecological patients in hospital and use of prophylaxis in Brazil.⁵⁹ From 1999 to 2001, data were collected on 27,450 patients. The registers showed that approximately one fourth of high-risk patients and half of moderate-risk patients were not given thromboprophylaxis, probably because of a lack of knowledge about risk factors and appropriate prophylactic strategies. No prophylactic measures whatsoever were used for two-thirds of the low-risk patients.

Pereira et al. conducted a prospective study with 850 patients admitted to the Hospital de Roraima to investigate whether DVT prophylaxis was being used correctly, according to the Caprini model.⁶⁰ Overall, 67% of the sample were clinical patients and 58% were classified as at medium or high risk of developing DVT. Just 24% of the patients who needed thromboprophylaxis were given it and the thromboprophylaxis provided was only classified as adequate in 20%. The authors concluded that ongoing education programs were needed.

Rocha et al.^{61,62} embarked on a project to implement a VTE prophylaxis program for clinical patients, setting up a commission, holding lectures, and distributing algorithms based on the Brazilian guidelines and assessing its impact on adequacy of thromboprophylaxis in hospitals in Salvador, in three phases. In the first phase, conducted in 2005, use and adequacy of prophylaxis were assessed with hospitalized clinical patients. In the second, 12-month phase, starting in 2007, a prophylaxis program was implemented. In the third phase, in 2008, the program's impact was evaluated. The authors concluded that risk factors are frequent among clinical patients, that there is great variation in the prophylaxis prescribed at public and private hospitals, and that only a minority of hospitalized clinical patients who were candidates for prophylaxis were given it at the correct dosage. They also concluded that ongoing education lectures and passive distribution of VTE prophylaxis algorithms were ineffective for improving utilization of prophylaxis, but did improve its appropriateness.^{61,62}

Okuhara et al.⁶³ conducted a study with 296 patients in hospital for vascular and orthopedic surgical procedures, to determine the incidence of DVT and the quality of the prophylaxis provided. The overall incidence of DVT was 7.5%. When put into risk

groups, 15% were classified as moderate risk, 24% as high risk and 50% as very high risk. Prophylaxis was correct in just 58%. The rates of appropriate prophylaxis were 72% for both the high and the very high risk groups. Excessive use of pharmacological prophylaxis was observed in 69% and 61% of the low and moderate risk groups, respectively. Although the majority of patients were considered high and very high risk, prophylaxis use continues to be deficient in medical practice.⁶³

Finally, the most recent cross-sectional study involving analysis of medical records in the city of Curitiba (published in 2017) compared use or not of prophylaxis within surgical and clinical specialties according to their VTE risk factors and showed that just 66% of the patients were given prophylaxis. In this study, 93% of clinical patients were given prophylaxis compared with 44% in the surgical group. Clinical patients at moderate and high risk were given more prophylaxis than surgical patients.⁶⁴

■ STRATEGIES TO INCREASE COMPLIANCE WITH GUIDELINES AND APPROPRIATE USE OF THROMBOPROPHYLAXIS

Several different studies have reported evidence that alerting health professionals to patients at risk of VTE increases the probability that prophylaxis will be used.

There are many different approaches and strategies. Simple didactic education and passive distribution of guidelines based on evidence alone are ineffective.^{65,66} Multiple and repeated application of different techniques to teach content, systems for alerting professionals with reminders to conduct risk assessments, and audits are all needed and it appears that a combination of these systems is in fact the most effective approach. One technique for increasing efficacy and use of thromboprophylaxis is implementation of electronic alert systems, which have been in use for 17 years. A randomized controlled study published in 2001, investigating a computerized system that automatically reminded physicians of the need for prophylaxis in hospitalized patients, showed that prophylactic heparin was administered to 32.2% of patients by a group of professionals using the electronic system and to 18.9% of patients by a group that was not using it.⁶⁷

In the United Kingdom, a computerized Clinical Decision Support (CDS) system was used to instruct and guide professionals to prescribe prophylaxis appropriately. The increases in compliance in response to reminders on computers are still modest,⁶⁸ but electronic alerts and computerized CDS systems do

increase rates of prescription to hospitalized clinical patients.^{69,70}

A cross-sectional study conducted in two phases (before and after implementation of a new VTE prophylaxis protocol) was conducted in a hospital in Porto Alegre (Brazil) to evaluate the impact on prophylaxis of a computerized CDS system combined with instructional seminars. Adequacy of prophylaxis increased from 46.2% to 57.9% in the before and after comparison between the two periods, and the increases were greatest among patients with cancer (18.1% to 44.1%) and those with three or more risk factors (25% to 42.9%).⁷¹

Despite the many initiatives and the increased use of VTE risk assessment, prophylaxis is still being underutilized today and there is also evidence of low compliance with published guidelines.^{72,73}

Lau & Haut conducted a MEDLINE search to identify studies published from 2001 to 2012 that evaluated the different types of interventions designed to improve use of VTE prophylaxis in hospitalized patients, classified according to the following parameters: exclusively educational, paper-based, computerized, real time auditing, or a combination of interventions.⁷⁴

There is robust evidence from many different high quality studies demonstrating the effectiveness of VTE prophylaxis in specific populations; however, risk stratification is needed to ensure that prophylaxis is targeted to the appropriate patients and, even then, prophylaxis rates remain sub-optimal and VTE continues to be a problem for patient safety. Furthermore, there is a lack of evidence to show which specific interventions are effective for increasing these prophylaxis rates. Education of professionals with no other interventions is not the best mechanism for increasing prophylaxis utilization.

Although derived from non-randomized studies without control patients and, therefore, considered of low quality, there is evidence to suggest that education combined with other strategies for quality improvement and technological initiatives, such as reminders and obligatory computerized CDS systems, is probably the best strategy to promote the practice of prophylaxis use, thereby avoiding harm to patients caused by VTE.

■ ACKNOWLEDGEMENTS

The authors thank Prof. Dr. Renato Braz de Araujo and Prof. Sonia Helena de Oliveira Raymundo Piteri for the final revision and correction of the Portuguese language.

■ REFERENCES

1. MacDougall DA, Feliu AL, Bocuzzi SJ, Lin J. Economic burden of deep vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. *Am J Health Syst Pharm.* 2006;63(20, Suppl 6):S5-15. <http://dx.doi.org/10.2146/ajhp060388>. PMID:17032933.
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008;133(6 Suppl):381S-453S.
3. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. *Am J Prev Med.* 2010;38(4, Suppl):S49S-501. <http://dx.doi.org/10.1016/j.amepre.2009.12.017>. PMID:20331949.
4. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. *J Thromb.* 2006;21(1):23-9. <http://dx.doi.org/10.1007/s11239-006-5572-y>. PMID:16475038.
5. Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. *J Thromb Thrombolysis.* 2009;28(4):458-64. <http://dx.doi.org/10.1007/s11239-009-0351-1>. PMID:19479199.
6. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. *Arch Intern Med.* 2000;160(6):809-15. <http://dx.doi.org/10.1001/archinte.160.6.809>. PMID:10737280.
7. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. *Circulation.* 2003;107(23, Suppl 1):I9-16. PMID:12814980.
8. Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R, Baigent C. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. *Health Technol Assess.* 2005;9(49):1-78.
9. Westrich GH, Rana AJ, Terry MA, Taveras NA, Kapoor K, Helfet DL. Thromboembolic disease prophylaxis in patients with hip fracture: a multimodal approach. *J Orthop Trauma.* 2005;19(4):234-40. <http://dx.doi.org/10.1097/01.bot.0000155307.20133.95>. PMID:15795571.
10. Kakkos SK, Caprini JA, Geroulakos G, Nicolaidis AN, Stansby G, Reddy DJ. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. *Eur J Vasc Endovasc Surg.* 2009;37(3):364-5. <http://dx.doi.org/10.1016/j.ejvs.2008.11.033>. PMID:19162515.
11. Cohen AT, Skinner JA, Warwick D, Brenkel I. The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicenter, multinational, randomized, open-label, parallel-group comparative study. *J Bone Joint Surg.* 2007;89(7):887-92. <http://dx.doi.org/10.1302/0301-620X.89B7.18556>. PMID:17673580.
12. Kakkor VV, Corrigan TP, Fossard DP. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. *Lancet.* 1975;2:45-51. PMID:49649.
13. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic and urologic surgery. *N Engl J Med.* 1988;318(18):1162-73. <http://dx.doi.org/10.1056/NEJM19880503181805>. PMID:3283548.
14. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous

- thromboembolism in general surgery. *Br J Surg*. 2001;88(7):913-30. <http://dx.doi.org/10.1046/j.0007-1323.2001.01800.x>. PMID:11442521.
15. Samama CM, Vray M, Barré J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. *Arch Intern Med*. 2002;162(19):2191-6. <http://dx.doi.org/10.1001/archinte.162.19.2191>. PMID:12390061.
 16. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. *Arch Intern Med*. 2002;162(16):1833-40. <http://dx.doi.org/10.1001/archinte.162.16.1833>. PMID:12196081.
 17. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. *Br J Surg*. 2005;92(10):1212-20. <http://dx.doi.org/10.1002/bjs.5154>. PMID:16175516.
 18. Cohen AT, Davidson BI, Gallus AS, et al. Efficacy and safety of fondaparinux for prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. *BMJ*. 2006;332(7537):325-9. <http://dx.doi.org/10.1136/bmj.38733.466748.7C>. PMID:16439370.
 19. Weitz JI, Hirsh J, Samama MM. New Antithrombotic drugs: American College of Chest Physicians Evidence-Based clinical Practice Guidelines (8th Edition). *Chest*. 2008; 133(6 Suppl):234S-56S. <http://dx.doi.org/10.1378/chest.08-0673>.
 20. Van Thiel D, Kalodiki E, Wahi R, Litinas E, Haque W, Rao G. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. *Clin Appl Thromb Hemost*. 2009;15(4):389-94. <http://dx.doi.org/10.1177/1076029609340163>. PMID:19608550.
 21. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med*. 2008;358(26):2765-75. <http://dx.doi.org/10.1056/NEJMoa0800374>. PMID:18579811.
 22. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. *Lancet*. 2008;372(9632):31-9. [http://dx.doi.org/10.1016/S0140-6736\(08\)60880-6](http://dx.doi.org/10.1016/S0140-6736(08)60880-6). PMID:18582928.
 23. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med*. 2008;358(26):2776-86. <http://dx.doi.org/10.1056/NEJMoa076016>. PMID:18579812.
 24. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial. *Lancet*. 2009;373(9676):1673-80. [http://dx.doi.org/10.1016/S0140-6736\(09\)60734-0](http://dx.doi.org/10.1016/S0140-6736(09)60734-0). PMID:19411100.
 25. Samama MM, Gerotziakas GT. Newer anticoagulants in 2009. *J Thromb Thrombolysis*. 2010;29(1):92-104. <http://dx.doi.org/10.1007/s11239-009-0392-5>. PMID:19838770.
 26. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. *N Engl J Med*. 2009;361(6):594-604. <http://dx.doi.org/10.1056/NEJMoa0810773>. PMID:19657123.
 27. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. *J Thromb Haemost*. 2007;5(12):2368-75. <http://dx.doi.org/10.1111/j.1538-7836.2007.02764.x>. PMID:17868430.
 28. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. *Lancet*. 2010;375(9717):807-15. [http://dx.doi.org/10.1016/S0140-6736\(09\)62125-5](http://dx.doi.org/10.1016/S0140-6736(09)62125-5). PMID:20206776.
 29. Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor versus enoxaparin for thromboprophylaxis after knee arthroplasty: the STARS E-3 trial. *Thromb Res*. 2014;134(6):1198-204. <http://dx.doi.org/10.1016/j.thromres.2014.09.011>. PMID:25294589.
 30. McBride BF. A preliminary assessment of the critical differences between novel oral anticoagulants currently in development. *J Clin Pharmacol*. 2005;45(9):1004-17. <http://dx.doi.org/10.1177/0091270005278084>. PMID:16100294.
 31. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. *Thromb Haemost*. 2009;101(1):77-85. <http://dx.doi.org/10.1160/TH08-07-0493>. PMID:19132192.
 32. Eikelboom JE, Weitz JI. Dabigatran etexilate for prevention of venous thromboembolism. *Thromb Haemost*. 2009;101(1):2-4. <http://dx.doi.org/10.1160/TH08-10-0708>. PMID:19132179.
 33. Rahme E, Dasgupta K, Burman M, et al. Post discharge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery. *CMAJ*. 2008;178(12):1545-54. <http://dx.doi.org/10.1503/cmaj.071388>. PMID:18519902.
 34. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized trials. *Lancet*. 2001;358(9275):9-15. [http://dx.doi.org/10.1016/S0140-6736\(00\)05249-1](http://dx.doi.org/10.1016/S0140-6736(00)05249-1). PMID:11454370.
 35. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. *Arch Intern Med*. 2003;163(11):1337-42. <http://dx.doi.org/10.1001/archinte.163.11.1337>. PMID:12796070.
 36. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. *Cochrane Database Syst Rev*. 2009;1(1):1-17. PMID:19160234.
 37. Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients. A trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of femur. *Lancet*. 1959;2(7110):981-9. [http://dx.doi.org/10.1016/S0140-6736\(59\)91464-3](http://dx.doi.org/10.1016/S0140-6736(59)91464-3). PMID:14445257.
 38. Prevention of venous thrombosis and pulmonary embolism. *Natl Inst Health Consens Dev Conf Consens Statement*. 1986;6(2):1-8. PMID:3528824.
 39. ACCP-NHLBI National Conference on Antithrombotic Therapy. American College of Chest Physicians; National Heart, Lung, and Blood Institute. ACCP-NHLBI National Conference on Antithrombotic Therapy. *Chest*. 1986;89(2, Suppl):1S-106S. PMID:3943407.
 40. Hirsh J, Dalen J, Guyatt G. Sixth ACCP consensus conference on antithrombotic therapy. *Chest*. 2001;119(1, Suppl):1S-370S. PMID:11157638.
 41. Guyatt GH, Cook DJ, Jaeschke R, Pauker SG, Schünemann HJ. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133(6 Suppl):123S-131S.
 42. Guyatt GH, Akl EA, Crowther M, Schünemann HJ, Gutterman DD, Lewis SZ. Introduction to the ninth edition. *Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.*: American College

- of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012; 141(2 Suppl):485-525.
43. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: A antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):535-705. <http://dx.doi.org/10.1378/chest.11-2288>.
 44. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. *N Engl J Med*. 1999;341(11):793-800. <http://dx.doi.org/10.1056/NEJM199909093411103>. PMID:10477777.
 45. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. *Am Heart J*. 2003;145(4):614-21. <http://dx.doi.org/10.1067/mhj.2003.189>. PMID:12679756.
 46. Leizerovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation*. 2004;110(7):874-9. <http://dx.doi.org/10.1161/01.CIR.0000138928.83266.24>. PMID:15289368.
 47. Sherman DG, Alberts GW, Bladin C, et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomized comparison. *Lancet*. 2007;369(9570):1347-55. [http://dx.doi.org/10.1016/S0140-6736\(07\)60633-3](http://dx.doi.org/10.1016/S0140-6736(07)60633-3). PMID:17448820.
 48. Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. *Chest*. 2007;132(3):936-45. <http://dx.doi.org/10.1378/chest.06-2993>. PMID:17573514.
 49. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboprophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. *Ann Intern Med*. 2010;153(1):8-18. <http://dx.doi.org/10.7326/0003-4819-153-1-201007060-00004>. PMID:20621900.
 50. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. *Lancet*. 2008;371(9610):387-94. [http://dx.doi.org/10.1016/S0140-6736\(08\)60202-0](http://dx.doi.org/10.1016/S0140-6736(08)60202-0). PMID:18242412.
 51. Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF. Low-molecular-weight heparin and mortality in acutely ill medical patients. *N Engl J Med*. 2011;365(26):2463-72. <http://dx.doi.org/10.1056/NEJMoa1111288>. PMID:22204723.
 52. Cohen AT, Spiro TE, Buller HR, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. *J Thromb Thrombolysis*. 2011;31(4):407-16. <http://dx.doi.org/10.1007/s11239-011-0549-x>. PMID:21359646.
 53. Taher AT, Aoun J, Salameh P. The AVAIL ME study: a multinational survey of VTE risk and prophylaxis. *J Thromb Thrombolysis*. 2011;31(1):47-56. <http://dx.doi.org/10.1007/s11239-010-0492-2>. PMID:20549305.
 54. Mokhtari M, Salameh P, Kouckek M, Kashani BS, Taher A, Waked M. The AVAIL ME Extension: a multinational Middle Eastern survey of venous thromboembolism risk and prophylaxis. *J Thromb Haemost*. 2011;9(7):1340-9. <http://dx.doi.org/10.1111/j.1538-7836.2011.04336.x>. PMID:21605327.
 55. Lilly CM, Liu X, Badawi O, Franey CS, Zuckerman IH. Thrombosis prophylaxis and mortality risk among critically ill adults. *Chest*. 2014;146(1):51-7. <http://dx.doi.org/10.1378/chest.13-2160>. PMID:24722879.
 56. Volschan A, Caramelli B, Gottschall CA, et al. Diretriz de embolia pulmonar. *Arq Bras Cardiol*. 2004;83(Suppl 1):1-8. <http://dx.doi.org/10.1590/S0066-782X2004002000001>. PMID:15311324.
 57. Rocha T, Paiva EF, Lichtenstein A. Tromboembolismo venoso: profilaxia em pacientes clínicos: parte 1. *Rev Assoc Med Bras*. 2009;55(2):95-107.
 58. Caiafa JS, Bastos M. Programa de profilaxia do tromboembolismo venoso do Hospital Naval Marcílio Dias: um modelo de educação continuada. *J Vasc Bras*. 2002;1(2):103-12.
 59. Caiafa JS, Bastos M, Moura LK, Raymundo S. Managing venous thromboembolism in Latin American patients: emerging results from the Brazilian Registry. *Semin Thromb Hemost*. 2002;28(s3, Suppl):47-50. <http://dx.doi.org/10.1055/s-2002-34076>. PMID:12232824.
 60. Pereira CA, Brito SS, Martins AS, Almeida CM. Profilaxia da trombose venosa profunda: aplicação prática e conhecimento teórico em um hospital geral. *J Vasc Bras*. 2008;7(1):18-27. <http://dx.doi.org/10.1590/S1677-54492008000100005>.
 61. Rocha ATC, Braga P, Ritt G, Lopes AA. Inadequação de tromboprophylaxia venosa em pacientes clínicos hospitalizados. *Rev Assoc Med Bras*. 2006;52(6):441-6. <http://dx.doi.org/10.1590/S0104-42302006000600026>. PMID:17242783.
 62. Rocha ATC, Paiva EF, Araújo DM, et al. Impacto de um programa para profilaxia de tromboembolismo venoso em pacientes clínicos em quatro hospitais de Salvador. *Rev Assoc Med Bras*. 2010;56(2):197-203. <http://dx.doi.org/10.1590/S0104-42302010000200019>. PMID:20498995.
 63. Okuhara A, Navarro TP, Procópio RJ, Bernardes RC, Oliveira LCC, Nishiyama MP. Incidência de trombose venosa profunda e qualidade da profilaxia para tromboembolismo venoso. *Rev Col Bras Cir*. 2014;41(1):2-6. <http://dx.doi.org/10.1590/S0100-69912014000100002>. PMID:24770766.
 64. Lopes BAC, Teixeira IP, Souza TD, Tafarel JR. Sabemos prescrever profilaxia de tromboembolismo venoso nos pacientes internados? *J Vasc Bras*. 2017;16(3):199-204. <http://dx.doi.org/10.1590/1677-5449.008516>. PMID:29930647.
 65. Kucher N, Puck M, Blaser J, Bucklar G, Eschmann E, Lüscher TF. Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients. *J Thromb Haemost*. 2009;7(8):1291-6. <http://dx.doi.org/10.1111/j.1538-7836.2009.03509.x>. PMID:19522743.
 66. Mazmanian PE, Davis DA, Galbraith R. Continuing medical education effect on clinical outcomes: effectiveness of continuing medical education: American College of Chest Physicians Evidence-Based Education Guidelines. *Chest*. 2009;135(3, Suppl):49S-55S. <http://dx.doi.org/10.1378/chest.08-2518>. PMID:19265076.
 67. Dexter PR, Perkins S, Overhage JM, Maharry K, Kohler BB, McDonald CJ. A computerized reminder system to increase the use of preventive care for hospitalized patients. *N Engl J Med*. 2001;345(13):965-70. <http://dx.doi.org/10.1056/NEJMsa010181>. PMID:11575289.
 68. Shojania KG, Jennings A, Mayhew A, Ramsay C, Eccles M, Grimshaw J. Effect of point-of-care computer reminders on physician behavior: a systematic review. *CMAJ*. 2010;182(5):E216-25. <http://dx.doi.org/10.1503/cmaj.090578>. PMID:20212028.
 69. Galanter WL, Thambi M, Rosencranz H, et al. Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital. *Am J*

Health Syst Pharm. 2010;67(15):1265-73. <http://dx.doi.org/10.2146/ajhp090575>. PMID:20651317.

70. Zeidan AM, Streiff MB, Lau BD, et al. Impact of a venous thromboembolism prophylaxis "smart order set": improved compliance, fewer events. *Am J Hematol*. 2013;88(7):545-9. <http://dx.doi.org/10.1002/ajh.23450>. PMID:23553743.
71. Fuzinato F, Waldemar FS, Wajner A, et al. A clinical decision support system for venous thromboembolism prophylaxis at a general hospital in a middle-income country. *J Bras Pneumol*. 2013;39(2):138-46. <http://dx.doi.org/10.1590/S1806-37132013000200004>. PMID:23670498.
72. Thavarajah D, Wetherill M. Implementing NICE guidelines on risk assessment for venous thromboembolism: failure, success and controversy. *Int J Health Care Qual Assur*. 2012;25(7):618-24. <http://dx.doi.org/10.1108/09526861211261217>. PMID:23276057.
73. Byrne S, Weaver DT. Review of thromboembolic prophylaxis in patients attending Cork University Hospital. *Int J Clin Pharm*. 2013;35(3):439-46. <http://dx.doi.org/10.1007/s11096-013-9760-5>. PMID:23494189.
74. Lau BD, Haut ER. Practices to prevent venous thromboembolism: a brief review. *BMJ Qual Saf*. 2014;23(3):187-95. <http://dx.doi.org/10.1136/bmjqs-2012-001782>. PMID:23708438.

Correspondence

Selma Regina de Oliveira Raymundo
Rua Antonio Bahia Monteiro, 465, sala 221 - Parque Residencial
Mançour Daud
CEP 15070-450 - São José do Rio Preto (SP), Brasil
Tel.: +55 (17) 99601-6062
E-mail: selma_ray@terra.com.br

Author information

SROR - MSc in Health Sciences, Faculdade de Medicina de São José do Rio Preto (FAMERP); Adjunct professor II-M, Serviço de Cirurgia Vascular e Angiologia, Departamento de Cardiologia e Cirurgia Vascular, Faculdade de Medicina de São José do Rio Preto; Full member, Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV); Board-certified in Angiology and Vascular Surgery, SBACV; Physician, Hospital Austa.

SMAL - Tenured professor, Faculdade de Medicina de São José do Rio Preto (FAMERP); Research adjunct director, Faculdade de Medicina de São José do Rio Preto; Chief, Serviço de Terapia Intensiva, Hospital de Base de São José do Rio Preto; Chief, Laboratório de Sepse, FAMERP; Board-certified in Intensive Therapy, Associação de Medicina Intensiva Brasileira (AMIB); Board-certified in Parenteral and Enteral Nutrition, Sociedade Brasileira de Nutrição Parenteral e Enteral (SBNPE); Elected future director (2020-2021), AMIB.

KMKH - Adjunct professor II-E, Faculdade de Medicina de São José do Rio Preto; Chief, Serviço de Vias Biliares e Pâncreas, Hospital de Base de São José do Rio Preto; Executive director, Grupo Austa.

KGH - Medical student, Faculdade FACERES.

ITS - Medical student, Faculdade FACERES.

Author contributions


Conception and design: SROR, KMKH, SMAL
Analysis and interpretation: SROR, SMAL
Data collection: SROR, KMKH, KGH, ITS
Writing the article: SROR, KMKH, SMAL, KGH, ITS
Critical revision of the article: SROR, KMKH, SMAL
Final approval of the article*: SROR, KMKH, SMAL, KGH, ITS
Statistical analysis: N/A.
Overall responsibility: SROR

* All authors have read and approved of the final version of the article submitted to *J Vasc Bras*.



O que mudou nas últimas décadas na profilaxia do tromboembolismo venoso em pacientes internados: artigo de revisão

What has changed in venous thromboembolism prophylaxis for hospitalized patients over recent decades: review article

Selma Regina de Oliveira Raymundo^{1,2} , Suzana Margareth Ajeje Lobo¹, Kassim Mohamede Kassim Hussain¹, Kassim Guzzon Hussein³, Isabela Tobal Secches³

Resumo

O tromboembolismo venoso (TEV) é uma doença frequente e de alta morbimortalidade, sendo considerada a maior causa evitável de mortalidade em pacientes hospitalizados. Apesar da incidência altíssima de TEV em todos os países e das evidências de que a trombopprofilaxia reduz as complicações tromboembólicas em pacientes clínicos e cirúrgicos, e a custo baixo, persistem grandes dúvidas quanto à segurança desse tipo de intervenção nos pacientes e quanto à trombopprofilaxia ideal. Inúmeros estudos e recomendações baseadas em evidências comprovam a eficácia da profilaxia na prevenção do TEV e/ou da morte dos pacientes, mas ainda hoje ela é subutilizada. Neste artigo, apresentamos uma ampla revisão dos métodos de profilaxia existentes até os dias atuais, publicados em diretrizes e estudos nacionais e internacionais sobre trombopprofilaxia.

Palavras-chave: tromboembolismo venoso; prevenção & controle; anticoagulantes.

Abstract

Venous thromboembolism (VTE) is a common disease with high rates of morbidity and mortality and is considered the number one cause of avoidable mortality among hospitalized patients. Although VTE incidence is extremely high in all countries and there is ample evidence that thromboprophylaxis inexpensively reduces the rate of thromboembolic complications in both clinical and surgical patients, a great deal of doubt remains with respect to patient safety with this type of intervention and in relation to the ideal thromboprophylaxis methods. Countless studies and evidence-based recommendations confirm the efficacy of prophylaxis for prevention of VTE and/or patient deaths, but it remains underutilized to this day. This article presents a wide-ranging review of existing prophylaxis methods up to the present, from guidelines and national and international studies of thromboprophylaxis.

Keywords: venous thromboembolism; prevention & control; anticoagulants.

Como citar: Raymundo SRO, Lobo SMA, Hussain KMK, Hussein KG, Secches IT. O que mudou nas últimas décadas na profilaxia do tromboembolismo venoso em pacientes internados: artigo de revisão. J Vasc Bras. 2019;18: e20180021. <https://doi.org/10.1590/1677-5449.002118>

¹Faculdade Regional de Medicina de São José do Rio Preto – FAMERP, Hospital de Base, São José do Rio Preto, SP, Brasil.

²Hospital Austa, São José do Rio Preto, SP, Brasil.

³Faculdade de Medicina em São José do Rio Preto – FACERES, São José do Rio Preto, SP, Brasil.

Fonte de financiamento: Nenhuma.

Conflitos de interesse: Os autores declararam não haver conflitos de interesse que precisam ser informados.

Submetido em: Maio 17, 2018. Aceito em: Novembro 13, 2018.

O estudo foi realizado no Hospital Austa, São José do Rio Preto, SP, Brasil.

■ INTRODUÇÃO

A trombose venosa profunda (TVP) e a embolia pulmonar (EP) constituem graves problemas de saúde pública nacional e internacional, devido aos altos custos associados a episódios agudos de tromboembolismo venoso (TEV) e a complicações a longo prazo^{1,2}. O TEV é uma séria complicação em pacientes hospitalizados e a causa mais frequente de morte evitável nesses pacientes, além de ser a terceira causa de morte de origem cardiovascular, após doença coronariana e acidente cerebrovascular³.

É evidente nos dias de hoje que pacientes clínicos são de risco para TEV tanto quanto pacientes cirúrgicos. Pacientes submetidos a cirurgia ortopédica, a cirurgia geral e com infarto agudo do miocárdio apresentam alto risco de TEV, e a proporção é quase igual nos pacientes cirúrgicos e clínicos (22% e 24% respectivamente)⁴. Entre pacientes submetidos a cirurgias abdominais, TEV sintomático tem uma taxa de 0,4 a 3,1%⁵.

A imobilização devido à paralisia de membros inferiores ou repouso por mais de 3 dias, assim como trauma grave e trauma raquimedular, aumenta o risco de trombose em até dez vezes, com efeito cumulativo com o tempo^{6,7}. Pacientes hospitalizados com doenças clínicas agudas também apresentam risco significativo: aproximadamente 10 a 30% dos pacientes clínicos podem evoluir com TEV². A insuficiência cardíaca congestiva (ICC) e insuficiência respiratória também aumentam o risco trombótico em até dez vezes⁷.

A frequência de complicações tromboembólicas em pacientes hospitalizados, as consequências adversas desses eventos e seu impacto econômico justificam a prioridade da tromboprofilaxia para segurança desses pacientes e constitui fator significativo para reduzir a morbidade a curto e longo prazo e a mortalidade. Entretanto, apesar da incidência altíssima de TEV registrada e publicada em vários estudos e das evidências de que a tromboprofilaxia reduz complicações tromboembólicas em pacientes clínicos e cirúrgicos a custo baixo, persistem grandes dúvidas quanto à segurança desse tipo de intervenção e quanto à forma ideal de profilaxia. Isso ocorre mesmo após mais de cinco décadas desde o primeiro estudo publicado demonstrando que o TEV sintomático e fatal poderia ser reduzido com a profilaxia, e quase 30 anos após a primeira diretriz baseada em evidências recomendando profilaxia na maioria dos pacientes hospitalizados.

Neste artigo, os autores fazem ampla revisão da literatura sobre tromboprofilaxia, com análise sistemática das referências bibliográficas nas bases de dados PubMed, SciELO, MEDLINE e LILACS no período de 1990-2017 e de artigos selecionados dos periódicos CAPES.

O objetivo deste artigo consiste em alertar sobre a necessidade da tromboprofilaxia e as estratégias para aumentar sua adesão pois, apesar de todos os esforços, esta ainda permanece insatisfatória no mundo todo.

■ MÉTODOS DE PROFILAXIA

Muitas opções de tromboprofilaxia estão atualmente disponíveis. Métodos não farmacológicos, incluindo meias elásticas de compressão graduada (MECG), compressão pneumática intermitente (CPI) e bombas venosas para pés, têm-se mostrado eficientes na redução de TVP em vários grupos de pacientes^{2,8}. Embora esses métodos mecânicos não aumentem o risco de sangramento, existem poucos estudos sobre esses dispositivos, e eles parecem ser menos eficazes que a profilaxia farmacológica em alguns grupos². Segundo evidências atuais, opções de profilaxia mecânica são mais utilizadas para pacientes com alto risco de sangramento ou combinadas com profilaxia farmacológica para tentar aumentar sua efetividade².

Várias estratégias de profilaxia efetivas, como a combinação de CPI, MECG ou farmacoprofilaxia [ácido acetilsalicílico (AAS) ou anticoagulantes] em pacientes de alto risco, não estão incluídas nas diretrizes, porque existem poucos ensaios clínicos randomizados, quando comparados a qualquer das opções recomendadas, e também porque essas combinações podem não ser mais efetivas, além de serem mais complexas e caras que as opções simples⁸⁻¹¹.

O *International Multicenter Trial*, conduzido por Kakkar, foi o ponto de referência para o início da farmacoprofilaxia, demonstrando que heparina não fracionada (HNF) 5.000 unidades internacionais (UI) subcutânea três vezes ao dia reduziu a TVP em 25%, enquanto que no grupo controle essa redução foi de 8%. A EP fatal diminuiu oito vezes em pacientes submetidos a cirurgias maiores¹². Uma metanálise realizada alguns anos após, com 46 ensaios clínicos randomizados, incluindo 15.000 pacientes cirúrgicos, demonstrou uma redução maior que 60% em TVP assintomática e EP fatal, bem como uma diminuição significativa na mortalidade mesmo quando utilizadas baixas doses de HNF¹³.

A heparina de baixo peso molecular (HBPM) é uma opção mais eficiente de profilaxia para um grande número de pacientes, tendendo a substituir a HNF^{2,14}. A HBPM tem rápido início de ação, dose única diária e, em muitos países, custo baixo. No Brasil, atualmente, são comercializados dois tipos de HBPM: enoxaparina e dalteparina.

Os antagonistas da vitamina K (AVK) orais, como a varfarina, têm sido usados na profilaxia de cirurgias ortopédicas maiores por várias décadas e, quando utilizados de forma correta, são eficazes na

redução do TEV, porém com algumas desvantagens: início de ação prolongada, variação grande na dose entre os pacientes e taxas maiores de sangramento na profilaxia estendida^{2,8,15}.

O inibidor indireto sintético do fator Xa (fondaparinux) mostrou maior eficácia que a HBPM em mais de 7.000 pacientes submetidos a cirurgia ortopédica em uma metanálise que incluiu quatro estudos randomizados¹⁶. Também foi eficaz em estudos de profilaxia em cirurgia geral e em pacientes clínicos^{17,18}.

Por muito tempo, os anticoagulantes disponíveis não preencheram os critérios de um anticoagulante teoricamente ideal, o que motivou pesquisas de novas moléculas, com farmacocinética e farmacodinâmica mais previsível e que se aproximassem desse perfil de eficácia, segurança e conforto posológico. Entre os anticoagulantes orais diretos¹⁹, rivaroxabana, apixabana e edoxabana (inibidores diretos do fator X) e etexilato de dabigatrana (inibidor direto da trombina) estão aprovados em alguns países para prevenção de TEV após artroplastia total de quadril (ATQ) e de joelho (ATJ). A rivaroxabana foi avaliada em quatro grandes estudos fase III. Esses estudos duplo-cegos, denominados *Regulation of Coagulation in Major Orthopaedic surgery Reducing Risk of Deep Venous Thrombosis and Pulmonary Embolism* (RECORD), incluíram mais de 12.500 pacientes submetidos a cirurgia eletiva de ATQ e ATJ e demonstraram a superioridade da rivaroxabana, na dose de 10 mg diária, com redução superior a 50% de risco nas taxas de TEV sintomática e de morte, quando comparada à enoxaparina 40 mg/dia²⁰. Contudo, o risco de sangramento foi de 0,7% com rivaroxabana contra 0,3% com enoxaparina.

O estudo RECORD1 comparou a eficácia da rivaroxabana com a da enoxaparina no pós-operatório durante 5 semanas em pacientes submetidos a ATQ e evidenciou redução de 70% do risco relativo no desfecho primário de eficácia com rivaroxabana²¹. O RECORD2 foi um estudo de superioridade para comparar a profilaxia estendida do TEV com 10 mg de rivaroxabana durante 35±4 dias com a profilaxia de curto prazo utilizando 40 mg de enoxaparina subcutânea durante 10-14 dias seguida por placebo oral até 35±4 dias após ATQ²². A tromboprofilaxia estendida com rivaroxabana foi significativamente mais eficaz, com redução de 79% do risco relativo no desfecho primário de eficácia e na prevenção de eventos sintomáticos.

O RECORD3 foi o primeiro estudo que mostrou a diminuição significativa do TEV sintomático em pacientes submetidos a ATJ, evidenciando a eficácia superior de uma posologia oral diária de 10 mg de rivaroxabana comparada à enoxaparina durante

10 a 14 dias²³. O RECORD4, por sua vez, comparou a eficácia de 10 mg de rivaroxabana ao dia com a de 30 mg de enoxaparina subcutânea duas vezes ao dia num período de 10 a 14 dias em pacientes submetidos a ATJ, demonstrando a não inferioridade da rivaroxabana e uma redução de 31% do risco relativo no desfecho de eficácia primária, além de reduções numéricas nos desfechos de eficácia secundária e no TEV sintomático, embora essas reduções não tenham sido significativas²⁴.

A apixabana tem fácil absorção oral e apresenta eliminação renal (25-30%) e hepática (65%)²⁵. No estudo ADVANCE1, a apixabana, na dose de 2,5 mg duas vezes ao dia, não se mostrou inferior quando comparada à enoxaparina (30 mg de 12 em 12 horas) em pacientes submetidos a ATJ, porém os desfechos e as taxas de mortalidade e TEV foram semelhantes, com menor taxa de sangramento com apixabana^{26,27}.

O estudo ADVANCE2, com pacientes submetidos a ATJ, comprovou que a apixabana, na dose de 2,5 mg duas vezes ao dia por 10 a 14 dias, foi mais eficaz que a enoxaparina (40 mg/dia), com segurança semelhante^{25,28}, e o estudo ADVANCE3 comparou a apixabana e enoxaparina durante 32 a 38 dias em pacientes submetidos a ATQ. A apixabana mostrou uma redução estatisticamente superior no desfecho primário (presença de TEV), na morte por todas as causas e no conjunto da TVP proximal, EP não fatal e morte relacionada com TEV.

A edoxabana na dose de 30 mg uma vez ao dia foi comparada à enoxaparina 20 mg de 12 em 12 horas em um estudo fase III de profilaxia em ATJ. Os resultados de eficácia da edoxabana foram superiores aos da enoxaparina nessa dosagem, e os de segurança (sangramentos) foram similares²⁹.

A dabigatrana foi usada para profilaxia de TVP em ATJ e ATQ em três estudos fase III (RE-MODEL, RE-MOBILIZE e RE-NOVATE), que demonstraram a não inferioridade em comparação à HBPM. A dabigatrana foi testada nas doses de 150 ou 220 mg/dia no pós-operatório de ATQ *versus* enoxaparina 40 mg/dia (RE-NOVATE) e *versus* enoxaparina 30 mg duas vezes ao dia (RE-MOBILIZE). A análise do desfecho primário foi a taxa de TVP, TEV e/ou morte por todas as causas^{25,30-32}.

Atualmente, sugere-se a extensão da profilaxia medicamentosa por até 35 dias em algumas situações, como cirurgias ortopédicas (ATJ, ATQ e cirurgia para fratura de quadril), pois a maioria dos eventos tromboembólicos sintomáticos é diagnosticada após a alta e o risco aumentado de TEV continua por mais de 3 meses após ATQ e por mais de 1 mês após ATJ³³.

Uma metanálise com nove estudos randomizados, abrangendo 4.000 pacientes submetidos a cirurgia ortopédica maior, evidenciou redução de risco de 51% para TVP e de 61% para TEV sintomático com profilaxia estendida, sem aumento no sangramento³⁴.

O uso estendido de fondaparinux por 7 dias em pacientes com fratura de quadril eliminou a TVP assintomática e o TEV sintomático³⁵. Embora a profilaxia de 4 a 6 semanas de profilaxia seja superior à profilaxia usada apenas no hospital, a duração ótima entre 2 e 6 semanas é incerta. Em pacientes submetidos a cirurgia oncológica de grande porte, a profilaxia estendida também é sugerida. Em dois estudos, a profilaxia estendida por 4 semanas nesses pacientes mostrou redução na taxa de TVP quando comparada a 1 semana apenas³⁶.

■ DIRETRIZES DE PROFILAXIA DAS AMERICAN COLLEGE OF CHEST PHYSICIANS (ACCP) EVIDENCE-BASED CLINICAL PRACTICE GUIDELINES

Em 1959, a publicação de ensaio controlado de trombopprofilaxia demonstrou que o uso de anticoagulante oral em pacientes submetidos a tratamento cirúrgico de fraturas de quadril reduziu TEV sintomático e morte, sem aumento de sangramento clinicamente significativo³⁷. A partir desse estudo, centenas de outros foram realizados e novas opções de profilaxia têm sido avaliadas, usadas, e, em alguns casos, substituídas por métodos mais efetivos e seguros. Desde 1986, foram publicadas mais de 25 diretrizes baseadas em evidência recomendando trombopprofilaxia de rotina na maioria dos pacientes hospitalizados^{2,38}. A cada 4 anos, o *American College of Chest Physicians (ACCP)* tem publicado diretrizes para tratamento e prevenção do TEV³⁹ que são referência no mundo todo. A partir da sexta edição das diretrizes do ACCP⁴⁰, adotou-se uma abordagem de qualidade na classificação de evidências e graus de recomendações. A oitava edição (AT8), de 2008, discute, separadamente, os riscos para 23 grupos de pacientes e as evidências para trombopprofilaxia com ênfase em ensaios clínicos randomizados² (ECR), e classifica as recomendações e a qualidade metodológica da evidência em⁴¹:

Grau de recomendação:

- Grau 1: os benefícios superam os riscos, encargos e custos;
- Grau 2: características individuais do paciente podem levar a diferentes escolhas.

Nível de evidência:

- A (alta qualidade): resultados são provenientes de ECR bem planejados e conduzidos, com grupos paralelos e controles adequados, análise de dados adequada e achados consistentes;
- B (moderada): provenientes de ECR com intervalo de confiança pequeno, estudos de coorte, caso-controle ou observacionais;
- C (baixa): resultado de estudos de coortes e caso-controle com baixa qualidade e alta probabilidade de viés.

Opções de recomendações a favor ou contra trombopprofilaxia foram descritas para cada grupo de pacientes, sendo recomendado que cada hospital desenvolvesse uma estratégia formal própria para prevenção de TEV (Grau 1A) e que a trombopprofilaxia deveria ser realizada em muitos pacientes hospitalizados. Não foi recomendado uso de AAS isolado para qualquer grupo de paciente (Grau 1A), e recomendou-se o uso de métodos mecânicos, principalmente para pacientes com alto risco de sangramento (Grau 1A) ou como adjuvante à farmacoprofilaxia (Grau 2A).

Na nona edição (AT9), de 2012, muitas recomendações de impacto menor substituíram as de maior impacto da AT8, devido à avaliação mais crítica de inferências que resultam em evidências e exclusão de especialistas com conflito de interesses no processo final das recomendações⁴². Uma limitação da AT8 foram as abordagens inconsistentes para avaliar o risco de sangramento, o que foi corrigido na AT9, sendo esse risco aplicado em todos os capítulos⁴³. Nessa edição, muitas novas recomendações foram incluídas, mas várias delas apresentavam baixo nível de evidência (2C).

■ ESTUDOS SOBRE PROFILAXIA EM PACIENTES CLÍNICOS

O *Prophylaxis in Medical Patients with Enoxaparin (MEDENOX)* foi o primeiro estudo multicêntrico randomizado que avaliou a eficácia e a segurança da farmacoprofilaxia em pacientes com doença clínica aguda e demonstrou o risco de TEV nesses pacientes.

Pacientes com mais de 40 anos admitidos com ICC, insuficiência respiratória aguda sem necessidade de suporte ventilatório, ou pacientes com outras condições clínicas e ao menos um fator de risco para TEV (idade superior a 75 anos, câncer, TEV prévio, hormonioterapia, obesidade, veias varicosas, insuficiência cardíaca ou respiratória crônica) foram randomizados para receberem placebo ou enoxaparina, diariamente, nas doses de 20 e 40 mg, durante um período de 6 a 14 dias. A incidência de TEV nos 1.102 pacientes foi significativamente menor no grupo

que recebeu 40 mg de enoxaparina (5,5%) do que nos grupos que receberam placebo (14,9%) e enoxaparina 20 mg (15%). O benefício observado com 40 mg de enoxaparina foi mantido por 3 meses. A incidência de efeitos adversos não diferiu significativamente entre o grupo placebo e o grupo enoxaparina⁴⁴. Esse estudo documentou, portanto, a incidência de TEV em pacientes clínicos e também estabeleceu a eficácia e a dose apropriada da profilaxia. Um risco aumentado de TEV após alta hospitalar também foi observado, visto que a taxa de TVP sintomática em 110 dias dobrou em relação à observada em 14 dias. O objetivo do estudo randomizado THE-PRINCE⁴⁵ foi determinar a eficácia e a segurança da enoxaparina 40 mg subcutânea, uma vez ao dia, ou de 5000 UI de HNF três vezes ao dia durante 10±2 dias, em pacientes com ICC ou doença respiratória severa. A incidência de TEV foi de 8,4% no grupo enoxaparina e de 10,4% no grupo HNF. Com enoxaparina constataram-se menos mortes e sangramentos e menos efeitos adversos. O estudo concluiu que enoxaparina é, no mínimo, tão efetiva quanto a HNF para prevenir TEV nesses pacientes clínicos e apresenta um melhor perfil de segurança.

No estudo multicêntrico e randomizado PREVENT⁴⁶, 1.518 pacientes clínicos receberam dalteparina 5.000 UI subcutânea uma vez ao dia e 1.473 receberam placebo por 14 dias. Dalteparina reduziu a taxa de TEV para 2,8%, sem aumento de hemorragia maior, comparado ao grupo placebo, com incidência de 4,9%. Esse estudo também mostrou a necessidade da farmacoprofilaxia nesses pacientes e estabeleceu a eficácia e a segurança da dalteparina.

O estudo ARTEMIS¹⁸ avaliou a eficácia e a segurança do fondaparinux 2,5 mg, quando utilizado por um período de 6 a 10 dias, na prevenção de TEV em pacientes clínicos mais idosos, em comparação ao placebo. A incidência de TEV foi de 10% nos pacientes que receberam placebo e de 5,6% nos que receberam fondaparinux.

O estudo PREVAIL⁴⁷, que avaliou o uso de HBPM em pacientes com acidente vascular cerebral isquêmico (AVCi), encontrou uma prevalência de TVP de 20 a 50% e observou que a EP foi a terceira causa de morte. Foram avaliados 1.762 pacientes que não andavam e apresentavam AVCi agudo com até 48 horas da admissão, os quais foram randomizados para receber HNF 5000 UI duas vezes ao dia ou enoxaparina 40 mg, em dose única diária, por 10 dias. A enoxaparina foi mais efetiva na redução de TEV nesses pacientes, de 18% contra 10% da HNF, com a mesma incidência de hemorragia intracraniana e extracraniana maior (1%).

O *International Medical Prevention Registry on Venous Thromboembolism* (IMPROVE), um estudo

observacional que avaliou práticas de prevenção de TEV em 15.156 pacientes clínicos hospitalizados em doze países por 4 anos, verificou que 50% dos pacientes receberam tromboprofilaxia medicamentosa ou mecânica. Nos EUA, 52% dos pacientes deveriam ter recebido tromboprofilaxia, mas somente 60% dos pacientes com fatores de risco para TEV a receberam. A HNF foi a mais usada nos EUA (20%), enquanto HBPM foi mais utilizada em outros países (40%)⁴⁸.

O estudo randomizado EXCLAIM⁴⁹ foi realizado com o objetivo de estabelecer a duração apropriada da tromboprofilaxia em pacientes com mais de 40 anos hospitalizados com doença clínica aguda e imobilização de até 3 dias. Nesse estudo, Foi prescrita enoxaparina 40 mg uma vez ao dia por 10±4 dias, seguida de enoxaparina 40 mg uma vez ao dia ou placebo por mais 28±4 dias. Comparado ao placebo, a terapia estendida com enoxaparina reduziu o risco relativo de todos os eventos de TEV em 44% (de 4,9% para 2,8%), de TEV assintomático em 34%, e de TEV sintomático em 73%. No subgrupo de pacientes com imobilidade nível 1 (repouso no leito completo), TEV foi observado em 2,5% dos pacientes com enoxaparina comparado com 4% no grupo placebo. O risco de sangramento maior foi de 0,8% no grupo com enoxaparina estendida e de 0,3% no grupo placebo. Esses resultados demonstraram um decréscimo de 1,5% na incidência de TEV proximal ou de EP às custas de um aumento de 0,5% na incidência de sangramento maior. O estudo concluiu que o regime estendido com enoxaparina é eficaz e seguro em pacientes clínicos que permanecem imobilizados.

Um grande estudo multicêntrico observacional avaliou a prevalência de TEV em pacientes hospitalizados clínicos com mais de 40 anos, ou maiores de 18 anos admitidos para tratamento cirúrgico ou devido a traumas, e a proporção de pacientes de risco que recebiam profilaxia apropriada (*Epidemiologic International Day for the Evaluation of Patients at Risk of Venous Thrombosis in the Acute Hospital Care Setting*, ENDORSE). Foram revisados 37.356 (55%) prontuários de pacientes clínicos e 30.827 (45%) de pacientes cirúrgicos, e foi usada a sétima edição das diretrizes do ACCP. Os pacientes considerados de risco para TEV variavam entre 36 e 73%⁵⁰. A proporção de pacientes de risco que receberam profilaxia apropriada variou de 2 a 84% em diferentes países. Entre pacientes cirúrgicos, 64,4% eram de risco para TEV, 58,5% receberam profilaxia e, apesar de 41,5% dos pacientes clínicos serem considerados de risco, somente 39,5% deles receberam profilaxia apropriada. Esse estudo demonstrou que, no total, mais de 50% dos pacientes clínicos hospitalizados necessitam de

profilaxia mas somente metade deles a recebe, e que a profilaxia é realizada em maior extensão nos pacientes cirúrgicos. Além disso, o estudo mostrou a existência de uma grande lacuna na administração adequada de profilaxia na população de risco, principalmente em pacientes clínicos.

Desde a publicação do estudo MEDENOX, a profilaxia com enoxaparina foi novamente avaliada em um estudo randomizado, duplo-cego, placebo controlado denominado *Low-Molecular-Weight Heparin and Mortality in Acutely Ill Medical Patients (LIFENOX)*, com o objetivo de verificar a mortalidade em 30 dias devido a qualquer causa após o uso de enoxaparina 40 mg subcutânea durante 10±4 dias, comparada ao placebo⁵¹. Foram incluídos pacientes acima de 40 anos de idade hospitalizados devido a ICC descompensada aguda, neoplasia ativa ou infecção sistêmica severa e com uma condição ou fator de risco adicional (doença pulmonar crônica, obesidade, história prévia de TEV ou idade ≥ 60 anos). Foram avaliados 8.307 pacientes internados por pelo menos 6 dias.

Em 30 dias, nenhuma diferença significativa foi observada entre os grupos enoxaparina e placebo no resultado primário de mortalidade por todas as causas (4,9% versus 4,8%, respectivamente). O estudo confirmou a necessidade do uso continuado de farmacoprofilaxia para prevenir TEV e suas complicações não fatais em pacientes hospitalizados clinicamente doentes. Todavia, esse estudo apresentou várias limitações: 1) a taxa de eventos no grupo placebo foi menor (4,8%) que a esperada (7%), e a taxa de EP fatal no grupo placebo foi menor que 0,1% em 30 dias; 2) os pacientes eram mais jovens, com menos sobrepeso e tinham menos eventos tromboembólicos prévios; 3) a mobilidade, um risco determinante maior para TEV, também não foi avaliada, o que pode ter levado à seleção de pacientes com taxas de eventos menores.

O estudo MAGELLAN⁵² comparou o uso de rivaroxabana 10 mg ao dia de profilaxia estendida por 35±4 dias com um regime padrão de 10±4 dias de enoxaparina (40 mg/dia, subcutânea) em pacientes clínicos agudamente doentes. Um total de 8.101 pacientes foi randomizado 1:1 para rivaroxabana estendida ou enoxaparina. Os resultados desse estudo confirmaram que eventos relacionados ao TEV continuaram a ocorrer após alta hospitalar. Houve um aumento de eventos no grupo controle de 2,7% em 10 dias para 5,7% em 35 dias e taxa de 4,4% no grupo rivaroxabana, comprovando sua eficácia em diminuir eventos; entretanto, dados sugerem que o risco aumentado de sangramento maior nesse grupo (1,1% versus 0,4%) pode não sugerir seu uso. Sangramento clinicamente relevante em 35 dias também foi observado em 4,1%

dos pacientes no grupo rivaroxabana e em 1,7% no grupo controle.

O estudo multinacional *Assessment for VTE management in hospital Middle East (AVAIL ME)*⁵³ foi realizado em pacientes clínicos e cirúrgicos com o objetivo primário de identificar a prevalência de pacientes com risco de TEV e definir a taxa de pacientes hospitalizados que receberam profilaxia de acordo com diretrizes de 2004 do ACCP. Os autores observaram que os fatores de risco e elegibilidade para profilaxia de TEV são comuns (mais que 80%), mas a profilaxia e aplicação das diretrizes foi baixa (37%), e mostraram que pacientes clínicos receberam menos profilaxia medicamentosa do que pacientes cirúrgicos.

O AVAIL ME Extension Project foi publicado em 2011. Dos pacientes elegíveis para receber profilaxia de TEV, 77% receberam alguma profilaxia medicamentosa, com 38% de adesão às diretrizes da AT8⁵⁴. Nesse estudo, embora aparentemente a profilaxia tivesse sido administrada mais frequentemente que em relatos anteriores, em uma porcentagem significativa de pacientes foi realizada profilaxia sem qualquer indicação clara (78%) ou na presença de contraindicações documentadas (66%), e os pacientes clínicos receberam menos profilaxia que os cirúrgicos.

Um estudo de coorte observacional nos EUA incluiu 294.896 pacientes criticamente doentes internados em unidade de terapia intensiva (UTI) e tratados com tromboprofilaxia farmacológica, com métodos mecânicos, com ambos, ou que não receberam profilaxia. O principal achado desse estudo é que pacientes adultos em UTI em uso de profilaxia com anticoagulantes apresentavam menor risco de mortalidade do que os que usavam métodos mecânicos ou que não utilizaram profilaxia alguma. Esses achados confirmam a recomendação da profilaxia medicamentosa em vez de profilaxia mecânica para pacientes críticos que não possuem contraindicação à anticoagulação⁵⁵.

■ ESTUDOS BRASILEIROS DE TROMBOPROFILAXIA

No Brasil, as diretrizes que abordam os fatores e a estratificação de risco de TEV e as recomendações tromboembólicas são apoiadas pela Associação Médica Brasileira^{56,57}.

Estudo desenvolvido entre 1995 e 1999 no Hospital Naval Marcílio Dias (Rio de Janeiro) analisou 18.690 pacientes utilizando a estratificação de risco de Caprini, sendo 5% deles classificados como de alto risco, 43% como intermediário, e 52% como de baixo risco. Os autores observaram que a profilaxia recomendada foi adotada em 47% dos pacientes de

alto risco, que 33% dos pacientes de risco moderado não receberam profilaxia, e que 4,6% dos pacientes de baixo risco receberam profilaxia medicamentosa, embora não houvesse indicação⁵⁸. Os quatro anos desse estudo piloto confirmaram a viabilidade e o valor do registro e mostraram um aumento considerável no uso de HBPM, associado à redução de seis vezes na incidência de TEV sintomático.

Um novo registro multicêntrico foi realizado para investigar a incidência e a distribuição de fatores de risco para TEV em pacientes clínicos, cirúrgicos e obstétrico-ginecológicos internados e o uso de profilaxia no Brasil⁵⁹. No período entre 1999 e 2001, foram coletados dados de 27.450 pacientes. Os registros mostraram que aproximadamente um quarto dos pacientes de alto risco e metade dos de moderado risco não receberam trombopprofilaxia, provavelmente devido à falta de conhecimento dos fatores de risco e estratégias profiláticas apropriadas. Em dois terços dos pacientes de baixo risco não foi realizada qualquer medida profilática.

Pereira et al. realizaram estudo prospectivo com 850 pacientes internados em um Hospital de Roraima para constatar se a profilaxia para TVP era utilizada de forma adequada, segundo o modelo de Caprini⁶⁰. Do total, 67% eram pacientes clínicos e 58% considerados de médio e alto risco para desenvolver TVP. Dos pacientes que necessitavam trombopprofilaxia, apenas 24% a receberam e apenas em 20% foi considerada adequada. Os autores concluíram que eram necessários programas de educação continuada.

Rocha et al.^{61,62} tinham como objetivo implementar um programa de profilaxia de TEV voltado para pacientes clínicos, com a criação de uma comissão, realização de palestras e distribuição de algoritmos baseados na diretriz brasileira e avaliar seu impacto na adequação da trombopprofilaxia em hospitais de Salvador em três etapas. Na primeira etapa, em 2005, foi avaliada a utilização e adequação da profilaxia nos pacientes clínicos internados. Na segunda etapa, a partir de 2007 e por 12 meses, foi implantado um programa de profilaxia. E na última etapa, em 2008, o impacto do programa foi avaliado. Os autores concluíram que os fatores de risco são frequentes em pacientes clínicos, que existe ampla variação na profilaxia prescrita em hospitais públicos e privados, e que apenas a minoria dos pacientes clínicos hospitalizados e candidatos à profilaxia recebem dosagem adequada. Concluíram também que aulas de educação continuada e distribuição passiva de algoritmos de profilaxia para TEV são insuficientes para melhorar a utilização da profilaxia, mas melhoram a sua adequação^{61,62}.

Okuhara et al.⁶³ desenvolveram um estudo com 296 pacientes internados submetidos a procedimentos

cirúrgicos vasculares e ortopédicos, para determinar a incidência de TVP e a qualidade de profilaxia utilizada. A incidência global de TVP foi de 7,5%. Quanto aos grupos de risco, 15% foram considerados de risco moderado, 24% de alto risco e 50% de altíssimo risco. A profilaxia foi correta em apenas 58%. As taxas de profilaxia adequada foram de 72% tanto no grupo de alto como no de altíssimo risco. O uso excessivo de farmacoprofilaxia foi evidenciado em 69% e 61% nos grupos de baixo e moderado risco, respectivamente. Embora a maior parte dos pacientes seja considerada de alto e altíssimo risco, na prática médica essa aplicação continua deficiente⁶³.

Por fim, o mais recente estudo transversal com análise de prontuários realizado em Curitiba e publicado em 2017 comparou o uso ou não da profilaxia nas especialidades clínicas e cirúrgicas de acordo com seu fator de risco para TEV e mostrou que apenas 66% dos pacientes receberam profilaxia. Dentre os pacientes clínicos, 93% receberam contra 44% do grupo cirúrgico. Pacientes clínicos de moderado a alto risco receberam mais profilaxia que os cirúrgicos⁶⁴.

■ ESTRATÉGIAS PARA AUMENTAR A ADERÊNCIA ÀS DIRETRIZES E AO USO APROPRIADO DA TROMBOPROFILAXIA

Vários estudos evidenciam que o alerta aos profissionais da saúde sobre os pacientes com risco de TEV aumenta a probabilidade do uso de profilaxia.

Muitas abordagens e estratégias existem. Educação didática simples ou disseminação passiva de diretrizes baseadas apenas em evidências não são efetivas^{65,66}. São necessárias múltiplas e repetitivas técnicas de conteúdo educacional, sistema de alertas como lembretes de avaliação de risco e auditorias, sendo a combinação desses sistemas parece ser, de fato, mais efetiva. Uma das maneiras para aumentar a eficácia e o uso de trombopprofilaxia é a implantação de sistemas de alertas eletrônicos, já usados há 17 anos. Um ensaio controlado randomizado, publicado em 2001, em que um sistema computadorizado lembrava automaticamente os médicos da necessidade da profilaxia em pacientes hospitalizados, mostrou que a heparina profilática era administrada em 32,2% dos pacientes no grupo dos profissionais que utilizavam o sistema eletrônico e em 18,9% dos pacientes no grupo que não o usavam⁶⁷.

No Reino Unido, o *Clinical Decision Support* (CDS), um sistema baseado em computador, tem sido uma forma de solicitar e orientar profissionais para prescrever profilaxia apropriadamente. Modificações na adesão deles com lembretes nos computadores ainda são modestas⁶⁸, mas alertas eletrônicos e CDS

computadorizados têm aumentado a prescrição em pacientes clínicos hospitalizados^{69,70}.

Estudo transversal em duas fases (antes e após implantação de um novo protocolo de profilaxia para TEV) foi realizado em hospital de Porto Alegre para avaliar o impacto da implantação na profilaxia de um sistema informatizado de suporte à decisão clínica combinado a seminários de orientação. A adequação da profilaxia aumentou de 46,2% para 57,9% quando foram comparados os dois períodos, principalmente em pacientes com câncer (de 18,1% para 44,1%) e naqueles com três ou mais fatores de risco (de 25% para 42,9%)⁷¹.

Apesar de muitas tentativas e do aumento nas avaliações de risco de TEV, a profilaxia é subutilizada até hoje, e existem algumas evidências da pequena aderência às diretrizes publicadas^{72,73}.

Lau & Haut conduziram uma pesquisa MEDLINE para identificar estudos publicados entre 2001 e 2012 que avaliavam os diversos tipos de intervenções para melhorar o uso de profilaxia de TEV em pacientes hospitalizados, de acordo com os seguintes parâmetros: educação somente, baseada em papéis, computadorizada, auditoria em tempo real, ou combinação de intervenções⁷⁴.

Fortes evidências de vários estudos de alta qualidade demonstram a efetividade da profilaxia do TEV para populações específicas; entretanto, é preciso estratificação de risco para assegurar que a profilaxia seja direcionada a pacientes apropriados e, mesmo assim, as taxas de profilaxia permanecem sub-ótimas e o TEV continua a ser um problema na segurança dos pacientes. Além disso, existem poucas evidências de quais intervenções específicas são efetivas para aumentar essas taxas de profilaxia. Educação apenas dos profissionais não é o melhor mecanismo para aumentar o uso da profilaxia.

Evidências, embora baseadas em estudos não randomizados sem pacientes controles e, portanto, considerados de baixa qualidade, apoiam que educação combinada com outras estratégias de melhoria de qualidade e abordagens tecnológicas, como alertas e apoio à decisão clínica informatizada obrigatória, provavelmente promova mais a prática do uso da profilaxia, evitando danos aos pacientes com TEV.

■ AGRADECIMENTOS

Os autores agradecem ao Prof. Dr. Renato Braz de Araujo e à Profa. Sonia Helena de Oliveira Raymundo Piteri pela revisão final e correção da língua portuguesa.

■ REFERÊNCIAS

1. MacDougall DA, Feliu AL, Bocuzzi SJ, Lin J. Economic burden of deep vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. *Am J Health Syst Pharm.* 2006;63(20, Suppl 6):S5-15. <http://dx.doi.org/10.2146/ajhp060388>. PMID:17032933.
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008;133(6 Suppl):381S-453S.
3. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. *Am J Prev Med.* 2010;38(4, Suppl):S49S-501. <http://dx.doi.org/10.1016/j.amepre.2009.12.017>. PMID:20331949.
4. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. *J Thromb.* 2006;21(1):23-9. <http://dx.doi.org/10.1007/s11239-006-5572-y>. PMID:16475038.
5. Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. *J Thromb Thrombolysis.* 2009;28(4):458-64. <http://dx.doi.org/10.1007/s11239-009-0351-1>. PMID:19479199.
6. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. *Arch Intern Med.* 2000;160(6):809-15. <http://dx.doi.org/10.1001/archinte.160.6.809>. PMID:10737280.
7. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. *Circulation.* 2003;107(23, Suppl 1):I9-16. PMID:12814980.
8. Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R, Baigent C. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. *Health Technol Assess.* 2005;9(49):1-78.
9. Westrich GH, Rana AJ, Terry MA, Taveras NA, Kapoor K, Helfet DL. Thromboembolic disease prophylaxis in patients with hip fracture: a multimodal approach. *J Orthop Trauma.* 2005;19(4):234-40. <http://dx.doi.org/10.1097/01.bot.0000155307.20133.95>. PMID:15795571.
10. Kakkos SK, Caprini JA, Geroulakos G, Nicolaidis AN, Stansby G, Reddy DJ. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. *Eur J Vasc Endovasc Surg.* 2009;37(3):364-5. <http://dx.doi.org/10.1016/j.ejvs.2008.11.033>. PMID:19162515.
11. Cohen AT, Skinner JA, Warwick D, Brenkel I. The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicenter, multinational, randomized, open-label, parallel-group comparative study. *J Bone Joint Surg.* 2007;89(7):887-92. <http://dx.doi.org/10.1302/0301-620X.89B7.18556>. PMID:17673580.
12. Kakkor VV, Corrigan TP, Fossard DP. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. *Lancet.* 1975;2:45-51. PMID:49649.
13. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic and urologic surgery. *N Engl J Med.* 1988;318(18):1162-73. <http://dx.doi.org/10.1056/NEJM19880503181805>. PMID:3283548.
14. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous

- thromboembolism in general surgery. *Br J Surg*. 2001;88(7):913-30. <http://dx.doi.org/10.1046/j.0007-1323.2001.01800.x>. PMID:11442521.
15. Samama CM, Vray M, Barré J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. *Arch Intern Med*. 2002;162(19):2191-6. <http://dx.doi.org/10.1001/archinte.162.19.2191>. PMID:12390061.
 16. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. *Arch Intern Med*. 2002;162(16):1833-40. <http://dx.doi.org/10.1001/archinte.162.16.1833>. PMID:12196081.
 17. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. *Br J Surg*. 2005;92(10):1212-20. <http://dx.doi.org/10.1002/bjs.5154>. PMID:16175516.
 18. Cohen AT, Davidson BI, Gallus AS, et al. Efficacy and safety of fondaparinux for prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. *BMJ*. 2006;332(7537):325-9. <http://dx.doi.org/10.1136/bmj.38733.466748.7C>. PMID:16439370.
 19. Weitz JI, Hirsh J, Samama MM. New Antithrombotic drugs: American College of Chest Physicians Evidence-Based clinical Practice Guidelines (8th Edition). *Chest*. 2008; 133(6 Suppl):234S-56S. <http://dx.doi.org/10.1378/chest.08-0673>.
 20. Van Thiel D, Kalodiki E, Wahi R, Litinas E, Haque W, Rao G. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. *Clin Appl Thromb Hemost*. 2009;15(4):389-94. <http://dx.doi.org/10.1177/1076029609340163>. PMID:19608550.
 21. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med*. 2008;358(26):2765-75. <http://dx.doi.org/10.1056/NEJMoa0800374>. PMID:18579811.
 22. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. *Lancet*. 2008;372(9632):31-9. [http://dx.doi.org/10.1016/S0140-6736\(08\)60880-6](http://dx.doi.org/10.1016/S0140-6736(08)60880-6). PMID:18582928.
 23. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med*. 2008;358(26):2776-86. <http://dx.doi.org/10.1056/NEJMoa076016>. PMID:18579812.
 24. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial. *Lancet*. 2009;373(9676):1673-80. [http://dx.doi.org/10.1016/S0140-6736\(09\)60734-0](http://dx.doi.org/10.1016/S0140-6736(09)60734-0). PMID:19411100.
 25. Samama MM, Gerotziakas GT. Newer anticoagulants in 2009. *J Thromb Thrombolysis*. 2010;29(1):92-104. <http://dx.doi.org/10.1007/s11239-009-0392-5>. PMID:19838770.
 26. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. *N Engl J Med*. 2009;361(6):594-604. <http://dx.doi.org/10.1056/NEJMoa0810773>. PMID:19657123.
 27. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. *J Thromb Haemost*. 2007;5(12):2368-75. <http://dx.doi.org/10.1111/j.1538-7836.2007.02764.x>. PMID:17868430.
 28. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. *Lancet*. 2010;375(9717):807-15. [http://dx.doi.org/10.1016/S0140-6736\(09\)62125-5](http://dx.doi.org/10.1016/S0140-6736(09)62125-5). PMID:20206776.
 29. Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor versus enoxaparin for thromboprophylaxis after knee arthroplasty: the STARS E-3 trial. *Thromb Res*. 2014;134(6):1198-204. <http://dx.doi.org/10.1016/j.thromres.2014.09.011>. PMID:25294589.
 30. McBride BF. A preliminary assessment of the critical differences between novel oral anticoagulants currently in development. *J Clin Pharmacol*. 2005;45(9):1004-17. <http://dx.doi.org/10.1177/0091270005278084>. PMID:16100294.
 31. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. *Thromb Haemost*. 2009;101(1):77-85. <http://dx.doi.org/10.1160/TH08-07-0493>. PMID:19132192.
 32. Eikelboom JE, Weitz JI. Dabigatran etexilate for prevention of venous thromboembolism. *Thromb Haemost*. 2009;101(1):2-4. <http://dx.doi.org/10.1160/TH08-10-0708>. PMID:19132179.
 33. Rahme E, Dasgupta K, Burman M, et al. Post discharge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery. *CMAJ*. 2008;178(12):1545-54. <http://dx.doi.org/10.1503/cmaj.071388>. PMID:18519902.
 34. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized trials. *Lancet*. 2001;358(9275):9-15. [http://dx.doi.org/10.1016/S0140-6736\(00\)05249-1](http://dx.doi.org/10.1016/S0140-6736(00)05249-1). PMID:11454370.
 35. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. *Arch Intern Med*. 2003;163(11):1337-42. <http://dx.doi.org/10.1001/archinte.163.11.1337>. PMID:12796070.
 36. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. *Cochrane Database Syst Rev*. 2009;1(1):1-17. PMID:19160234.
 37. Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients. A trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of femur. *Lancet*. 1959;2(7110):981-9. [http://dx.doi.org/10.1016/S0140-6736\(59\)91464-3](http://dx.doi.org/10.1016/S0140-6736(59)91464-3). PMID:14445257.
 38. Prevention of venous thrombosis and pulmonary embolism. *Natl Inst Health Consens Dev Conf Consens Statement*. 1986;6(2):1-8. PMID:3528824.
 39. ACCP-NHLBI National Conference on Antithrombotic Therapy. American College of Chest Physicians; National Heart, Lung, and Blood Institute. ACCP-NHLBI National Conference on Antithrombotic Therapy. *Chest*. 1986;89(2, Suppl):1S-106S. PMID:3943407.
 40. Hirsh J, Dalen J, Guyatt G. Sixth ACCP consensus conference on antithrombotic therapy. *Chest*. 2001;119(1, Suppl):1S-370S. PMID:11157638.
 41. Guyatt GH, Cook DJ, Jaeschke R, Pauker SG, Schünemann HJ. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133(6 Suppl):123S-131S.
 42. Guyatt GH, Akl EA, Crowther M, Schünemann HJ, Gutterman DD, Lewis SZ. Introduction to the ninth edition. *Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.*: American College

- of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012; 141(2 Suppl):485-525.
43. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: A antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):535-705. <http://dx.doi.org/10.1378/chest.11-2288>.
 44. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaprin Study Group. *N Engl J Med*. 1999;341(11):793-800. <http://dx.doi.org/10.1056/NEJM199909093411103>. PMID:10477777.
 45. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. *Am Heart J*. 2003;145(4):614-21. <http://dx.doi.org/10.1067/mhj.2003.189>. PMID:12679756.
 46. Leizerovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation*. 2004;110(7):874-9. <http://dx.doi.org/10.1161/01.CIR.0000138928.83266.24>. PMID:15289368.
 47. Sherman DG, Alberts GW, Bladin C, et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomized comparison. *Lancet*. 2007;369(9570):1347-55. [http://dx.doi.org/10.1016/S0140-6736\(07\)60633-3](http://dx.doi.org/10.1016/S0140-6736(07)60633-3). PMID:17448820.
 48. Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. *Chest*. 2007;132(3):936-45. <http://dx.doi.org/10.1378/chest.06-2993>. PMID:17573514.
 49. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboprophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. *Ann Intern Med*. 2010;153(1):8-18. <http://dx.doi.org/10.7326/0003-4819-153-1-201007060-00004>. PMID:20621900.
 50. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. *Lancet*. 2008;371(9610):387-94. [http://dx.doi.org/10.1016/S0140-6736\(08\)60202-0](http://dx.doi.org/10.1016/S0140-6736(08)60202-0). PMID:18242412.
 51. Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF. Low-molecular-weight heparin and mortality in acutely ill medical patients. *N Engl J Med*. 2011;365(26):2463-72. <http://dx.doi.org/10.1056/NEJMoa1111288>. PMID:22204723.
 52. Cohen AT, Spiro TE, Buller HR, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. *J Thromb Thrombolysis*. 2011;31(4):407-16. <http://dx.doi.org/10.1007/s11239-011-0549-x>. PMID:21359646.
 53. Taher AT, Aoun J, Salameh P. The AVAIL ME study: a multinational survey of VTE risk and prophylaxis. *J Thromb Thrombolysis*. 2011;31(1):47-56. <http://dx.doi.org/10.1007/s11239-010-0492-2>. PMID:20549305.
 54. Mokhtari M, Salameh P, Kouček M, Kashani BS, Taher A, Waked M. The AVAIL ME Extension: a multinational Middle Eastern survey of venous thromboembolism risk and prophylaxis. *J Thromb Haemost*. 2011;9(7):1340-9. <http://dx.doi.org/10.1111/j.1538-7836.2011.04336.x>. PMID:21605327.
 55. Lilly CM, Liu X, Badawi O, Franey CS, Zuckerman IH. Thrombosis prophylaxis and mortality risk among critically ill adults. *Chest*. 2014;146(1):51-7. <http://dx.doi.org/10.1378/chest.13-2160>. PMID:24722879.
 56. Volschan A, Caramelli B, Gottschall CA, et al. Diretriz de embolia pulmonar. *Arq Bras Cardiol*. 2004;83(Suppl 1):1-8. <http://dx.doi.org/10.1590/S0066-782X2004002000001>. PMID:15311324.
 57. Rocha T, Paiva EF, Lichtenstein A. Tromboembolismo venoso: profilaxia em pacientes clínicos: parte 1. *Rev Assoc Med Bras*. 2009;55(2):95-107.
 58. Caiafa JS, Bastos M. Programa de profilaxia do tromboembolismo venoso do Hospital Naval Marcílio Dias: um modelo de educação continuada. *J Vasc Bras*. 2002;1(2):103-12.
 59. Caiafa JS, Bastos M, Moura LK, Raymundo S. Managing venous thromboembolism in Latin American patients: emerging results from the Brazilian Registry. *Semin Thromb Hemost*. 2002;28(s3, Suppl):47-50. <http://dx.doi.org/10.1055/s-2002-34076>. PMID:12232824.
 60. Pereira CA, Brito SS, Martins AS, Almeida CM. Profilaxia da trombose venosa profunda: aplicação prática e conhecimento teórico em um hospital geral. *J Vasc Bras*. 2008;7(1):18-27. <http://dx.doi.org/10.1590/S1677-54492008000100005>.
 61. Rocha ATC, Braga P, Ritt G, Lopes AA. Inadequação de tromboprophylaxia venosa em pacientes clínicos hospitalizados. *Rev Assoc Med Bras*. 2006;52(6):441-6. <http://dx.doi.org/10.1590/S0104-42302006000600026>. PMID:17242783.
 62. Rocha ATC, Paiva EF, Araújo DM, et al. Impacto de um programa para profilaxia de tromboembolismo venoso em pacientes clínicos em quatro hospitais de Salvador. *Rev Assoc Med Bras*. 2010;56(2):197-203. <http://dx.doi.org/10.1590/S0104-42302010000200019>. PMID:20498995.
 63. Okuhara A, Navarro TP, Procópio RJ, Bernardes RC, Oliveira LCC, Nishiyama MP. Incidência de trombose venosa profunda e qualidade da profilaxia para tromboembolismo venoso. *Rev Col Bras Cir*. 2014;41(1):2-6. <http://dx.doi.org/10.1590/S0100-69912014000100002>. PMID:24770766.
 64. Lopes BAC, Teixeira IP, Souza TD, Tafarel JR. Sabemos prescrever profilaxia de tromboembolismo venoso nos pacientes internados? *J Vasc Bras*. 2017;16(3):199-204. <http://dx.doi.org/10.1590/1677-5449.008516>. PMID:29930647.
 65. Kucher N, Puck M, Blaser J, Bucklar G, Eschmann E, Lüscher TF. Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients. *J Thromb Haemost*. 2009;7(8):1291-6. <http://dx.doi.org/10.1111/j.1538-7836.2009.03509.x>. PMID:19522743.
 66. Mazmanian PE, Davis DA, Galbraith R. Continuing medical education effect on clinical outcomes: effectiveness of continuing medical education: American College of Chest Physicians Evidence-Based Education Guidelines. *Chest*. 2009;135(3, Suppl):49S-55S. <http://dx.doi.org/10.1378/chest.08-2518>. PMID:19265076.
 67. Dexter PR, Perkins S, Overhage JM, Maharry K, Kohler BB, McDonald CJ. A computerized reminder system to increase the use of preventive care for hospitalized patients. *N Engl J Med*. 2001;345(13):965-70. <http://dx.doi.org/10.1056/NEJMsa010181>. PMID:11575289.
 68. Shojania KG, Jennings A, Mayhew A, Ramsay C, Eccles M, Grimshaw J. Effect of point-of-care computer reminders on physician behavior: a systematic review. *CMAJ*. 2010;182(5):E216-25. <http://dx.doi.org/10.1503/cmaj.090578>. PMID:20212028.
 69. Galanter WL, Thambi M, Rosencranz H, et al. Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital. *Am J*

Health Syst Pharm. 2010;67(15):1265-73. <http://dx.doi.org/10.2146/ajhp090575>. PMID:20651317.

70. Zeidan AM, Streiff MB, Lau BD, et al. Impact of a venous thromboembolism prophylaxis "smart order set": improved compliance, fewer events. *Am J Hematol.* 2013;88(7):545-9. <http://dx.doi.org/10.1002/ajh.23450>. PMID:23553743.
71. Fuzinato F, Waldemar FS, Wajner A, et al. A clinical decision support system for venous thromboembolism prophylaxis at a general hospital in a middle-income country. *J Bras Pneumol.* 2013;39(2):138-46. <http://dx.doi.org/10.1590/S1806-37132013000200004>. PMID:23670498.
72. Thavarajah D, Wetherill M. Implementing NICE guidelines on risk assessment for venous thromboembolism: failure, success and controversy. *Int J Health Care Qual Assur.* 2012;25(7):618-24. <http://dx.doi.org/10.1108/09526861211261217>. PMID:23276057.
73. Byrne S, Weaver DT. Review of thromboembolic prophylaxis in patients attending Cork University Hospital. *Int J Clin Pharm.* 2013;35(3):439-46. <http://dx.doi.org/10.1007/s11096-013-9760-5>. PMID:23494189.
74. Lau BD, Haut ER. Practices to prevent venous thromboembolism: a brief review. *BMJ Qual Saf.* 2014;23(3):187-95. <http://dx.doi.org/10.1136/bmjqs-2012-001782>. PMID:23708438.

Correspondência

Selma Regina de Oliveira Raymundo
 Rua Antonio Bahia Monteiro, 465, sala 221 - Parque Residencial
 Mançour Daud
 CEP 15070-450 - São José do Rio Preto (SP), Brasil
 Tel.: (17) 99601-6062
 E-mail: selma_ray@terra.com.br

Informações sobre os autores:

SROR - Mestre em Ciências da Saúde, Faculdade de Medicina de São José do Rio Preto (FAMERP); Professora adjunta II-M, Serviço de Cirurgia Vasculare Angiologia, Departamento de Cardiologia e Cirurgia Vasculare, Faculdade de Medicina de São José do Rio Preto; Titular, Sociedade Brasileira de Angiologia e Cirurgia Vasculare (SBACV); Especialista em angiologia e cirurgia vascular, SBACV; Médica do Hospital Austa.
 SMAL - Livre-docente, Faculdade de Medicina de São José do Rio Preto (FAMERP); Diretora adjunta de Pesquisa, Faculdade de Medicina de São José do Rio Preto; Chefe, Serviço de Terapia Intensiva, Hospital de Base de São José do Rio Preto; Chefe, Laboratório de Sepsis, FAMERP; Especialista em terapia intensiva, Associação de Medicina Intensiva Brasileira (AMIB); Especialista em nutrição parenteral e enteral, Sociedade Brasileira de Nutrição Parenteral e Enteral (SBNPE); Diretora futura (2020-2021), AMIB.
 KMKH - Professor Adjunto II-E, Faculdade de Medicina de São José do Rio Preto; Chefe, Serviço de Vias biliares e pâncreas, Hospital de Base de São José do Rio Preto; Diretor executivo, grupo Austa.
 KGH - Discente de Medicina, Faculdade FACERES.
 ITS - Discente de Medicina, Faculdade FACERES.

Contribuição dos autores

Concepção e desenho do estudo: SROR, KMKH, SMAL
 Análise e interpretação dos dados: SROR, SMAL
 Coleta de dados: SROR, KMKH, KGH, ITS
 Redação do artigo: SROR, KMKH, SMAL, KGH, ITS
 Revisão crítica do texto: SROR, KMKH, SMAL
 Aprovação final do artigo*: SROR, KMKH, SMAL, KGH, ITS
 Análise estatística: N/A.
 Responsabilidade geral pelo estudo: SROR

*Todos os autores leram e aprovaram a versão final submetida do J Vasc Bras.